



Clinical trial results:

A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed

Summary

EudraCT number	2014-005147-40
Trial protocol	ES DE NL BE GB IT
Global end of trial date	

Results information

Result version number	v6
This version publication date	06 November 2020
First version publication date	13 August 2017
Version creation reason	• New data added to full data set 202094 study results - Sub study of 201636 and 201637 studies (EudraCT #2014-005147-40 & #2014-005148-16)
Summary attachment (see zip file)	202094 study results - Sub study of 201636 and 201637 studies (EudraCT #2014-005147-40 & #2014-005148-16) (Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen - 202094 Study Results.pdf)

Trial information

Trial identification

Sponsor protocol code	201636
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	ViiV Healthcare
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom,
Public contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 8664357343,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No	No

1901/2006 apply to this trial?	
--------------------------------	--

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	20 February 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	16 September 2016
Global end of trial reached?	No

Notes:

General information about the trial

Main objective of the trial:

To demonstrate the non-inferior antiviral activity of switching to dolutegravir (DTG) plus rilpivirine (RPV) once daily compared to continuation of current antiretroviral regimen (CAR) over 48 weeks in HIV-1 infected antiretroviral therapy (ART)-experienced virologically suppressed subjects

Protection of trial subjects:

Not applicable

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	14 April 2015
Long term follow-up planned	Yes
Long term follow-up rationale	Scientific research
Long term follow-up duration	4 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 191
Country: Number of subjects enrolled	Taiwan: 54
Country: Number of subjects enrolled	United Kingdom: 3
Country: Number of subjects enrolled	United States: 86
Country: Number of subjects enrolled	Argentina: 5
Country: Number of subjects enrolled	Australia: 10
Country: Number of subjects enrolled	Belgium: 18
Country: Number of subjects enrolled	Canada: 29
Country: Number of subjects enrolled	France: 33
Country: Number of subjects enrolled	Germany: 17
Country: Number of subjects enrolled	Italy: 20
Country: Number of subjects enrolled	Netherlands: 9
Country: Number of subjects enrolled	Russian Federation: 35
Worldwide total number of subjects	510
EEA total number of subjects	291

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	490
From 65 to 84 years	20
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study was a 148-week, Phase III, randomized, open-label, active-controlled, multicenter, parallel-group, non-inferiority study to assess the antiviral activity and safety of a two-drug regimen of dolutegravir (DTG) + rilpivirine (RPV) compared with current antiretroviral regimen (CAR). The study was conducted at 65 centers in 13 countries.

Pre-assignment

Screening details:

Total 641 participants were screened (131 failed), 510 participants were randomized and 2 participants withdrew before being exposed to study drug. The study included a Screening phase, an early switch phase, a late switch phase, and a continuation phase. The results presented are based on the interim analysis of the Late Switch Phase (Week 148).

Period 1

Period 1 title	Early Switch Phase (Up to Week 52)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	DTG + RPV

Arm description:

Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.

Arm type	Experimental
Investigational medicinal product name	Dolutegravir Tablets 50 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received dolutegravir tablets 50 mg once daily, with a meal, in an open-label fashion up to Week 52 during early switch phase.

Investigational medicinal product name	Rilpivirine Tablets 25 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received rilpivirine tablets 25 mg once daily, with a meal, in an open-label fashion up to Week 52 during early switch phase.

Arm title	Current antiretroviral regimen
-----------	--------------------------------

Arm description:

Participants continued to receive their current antiretroviral regimen (two nucleoside reverse transcriptase inhibitors [NRTIs] + a third agent). A third agent included either an: integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). CAR was administered according to the approved labeling in an open-label fashion up to Week 52 during early switch phase. At Week 52, participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) <50 copies per milliliter (c/mL), switched to DTG 50 mg + RPV 25 mg once daily and were followed until Week 148.

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	Current antiretroviral regimen (not IMP)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received their current antiretroviral regimen (2 NRTIs + a third agent). A third agent included either of INI, NNRTI, or PI. CAR was administered according to the approved labeling in an open-label fashion up to Week 52 during early switch phase.

Number of subjects in period 1^[1]	DTG + RPV	Current antiretroviral regimen
Started	252	256
Completed	239	238
Not completed	13	18
Consent withdrawn by subject	3	7
Physician decision	-	2
Adverse event, non-fatal	6	2
Lost to follow-up	1	2
Lack of efficacy	2	1
Protocol deviation	1	4

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Total number of participants enrolled were 510. Of which, 2 participants withdrew before being exposed to study drug.

Period 2

Period 2 title	Late Switch Phase (Week 52 to Week 148)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	DTG + RPV

Arm description:

Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.

Arm type	Experimental
Investigational medicinal product name	Rilpivirine Tablets 25 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received rilpivirine tablets 25 mg once daily, with a meal, in an open-label fashion up to Week 148 during late switch phase.

Investigational medicinal product name	Dolutegravir Tablets 50 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received dolutegravir tablets 50 mg once daily, with a meal, in an open-label fashion up to Week 148 during late switch phase.

Arm title	Current antiretroviral regimen
------------------	--------------------------------

Arm description:

Participants continued to receive their current antiretroviral regimen (two nucleoside reverse transcriptase inhibitors [NRTIs] + a third agent). A third agent included either an: integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). CAR was administered according to the approved labeling in an open-label fashion up to Week 52 during early switch phase. At Week 52, participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) <50 copies per milliliter (c/mL), switched to DTG 50 mg + RPV 25 mg once daily and were followed until Week 148.

Arm type	Active comparator
Investigational medicinal product name	Dolutegravir Tablets 50 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received dolutegravir tablets 50 mg once daily, with a meal, in an open-label fashion from Week 52 to Week 148 during late switch phase.

Investigational medicinal product name	Rilpivirine Tablets 25 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received rilpivirine tablets 25 mg once daily, with a meal, in an open-label fashion from Week 52 to Week 148 during late Switch phase.

Number of subjects in period 2	DTG + RPV	Current antiretroviral regimen
Started	239	238
Completed	214	210
Not completed	25	28
Consent withdrawn by subject	7	5
Physician decision	-	4
Adverse event, non-fatal	11	12
Lost to follow-up	-	1
Lack of efficacy	4	3
Protocol deviation	3	3

Baseline characteristics

Reporting groups

Reporting group title	DTG + RPV
-----------------------	-----------

Reporting group description:

Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.

Reporting group title	Current antiretroviral regimen
-----------------------	--------------------------------

Reporting group description:

Participants continued to receive their current antiretroviral regimen (two nucleoside reverse transcriptase inhibitors [NRTIs] + a third agent). A third agent included either an: integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). CAR was administered according to the approved labeling in an open-label fashion up to Week 52 during early switch phase. At Week 52, participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) <50 copies per milliliter (c/mL), switched to DTG 50 mg + RPV 25 mg once daily and were followed until Week 148.

Reporting group values	DTG + RPV	Current antiretroviral regimen	Total
Number of subjects	252	256	508
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	242	246	488
From 65-84 years	10	10	20
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	43.6	43.6	
standard deviation	± 10.93	± 10.76	-
Sex: Female, Male Units: Subjects			
Female	58	51	109
Male	194	205	399
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	3	6	9
Japanese/East Asian (EA) Heritage (H.)/South EA H.	25	34	59
Black/African American	24	27	51
Native Hawaiian or other Pacific Islander	1	0	1
White	198	188	386
American Indian or Alaska Native and white	0	1	1

African American/African H. and Asian	1	0	1
---------------------------------------	---	---	---

End points

End points reporting groups

Reporting group title	DTG + RPV
Reporting group description: Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.	
Reporting group title	Current antiretroviral regimen
Reporting group description: Participants continued to receive their current antiretroviral regimen (two nucleoside reverse transcriptase inhibitors [NRTIs] + a third agent). A third agent included either an: integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). CAR was administered according to the approved labeling in an open-label fashion up to Week 52 during early switch phase. At Week 52, participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) <50 copies per milliliter (c/mL), switched to DTG 50 mg + RPV 25 mg once daily and were followed until Week 148.	
Reporting group title	DTG + RPV
Reporting group description: Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.	
Reporting group title	Current antiretroviral regimen
Reporting group description: Participants continued to receive their current antiretroviral regimen (two nucleoside reverse transcriptase inhibitors [NRTIs] + a third agent). A third agent included either an: integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). CAR was administered according to the approved labeling in an open-label fashion up to Week 52 during early switch phase. At Week 52, participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) <50 copies per milliliter (c/mL), switched to DTG 50 mg + RPV 25 mg once daily and were followed until Week 148.	
Subject analysis set title	DTG 50 mg PK Parameter Population
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants received DTG 50 mg + RPV 25 mg together once daily, with a meal, in an open-label fashion up to Week 52 during early switch phase. The arm is specific for participants in the PK Parameter Population.	
Subject analysis set title	RPV 25 mg PK Parameter Population
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants received DTG 50 mg + RPV 25 mg together once daily, with a meal, in an open-label fashion up to Week 52 during early switch phase. The arm is specific for participants in the PK Parameter Population.	
Subject analysis set title	CAR-DTG 50 mg LS PK Parameter Population
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants from CAR arm received DTG 50 mg + RPV 25 mg together once daily, with a meal, in an open-label fashion from Week 52 to Week 148 during late switch phase. The arm is specific for participants in LS PK Parameter Population.	
Subject analysis set title	CAR-RPV 25 mg LS PK Parameter Population
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants from CAR arm received DTG 50 mg +RPV 25 mg together once daily, with a meal, in an open-label fashion from Week 52 to Week 148 during late switch phase. The arm is specific for participants in LS PK Parameter Population.	
Subject analysis set title	DTG 50 mg PK Parameter NNRTI Subset
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received DTG 50 mg + RPV 25 mg together once daily, with a meal, in an open-label fashion up to Week 52 during early switch phase. The arm is specific for participants in PK Parameter NNRTI Subset extra sampling Population.

Subject analysis set title	RPV 25 mg PK Parameter NNRTI Subset
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received DTG 50 mg + RPV 25 mg together once daily, with a meal, in an open-label fashion up to Week 52 during early switch phase. The arm is specific for participants in PK Parameter NNRTI Subset extra sampling Population.

Primary: Percentage of participants with plasma HIV-1 RNA <50 c/mL at Week 48 using snapshot algorithm

End point title	Percentage of participants with plasma HIV-1 RNA <50 c/mL at Week 48 using snapshot algorithm
-----------------	---

End point description:

Percentage of participants with plasma HIV 1 RNA < 50 c/mL at Week 48 using the Food and Drug Administration (FDA) snapshot algorithm was assessed to demonstrate the non-inferior antiviral activity of switching to DTG + RPV once daily compared to continuation of CAR over 48 weeks in HIV-1 infected antiretroviral therapy (ART)-experienced participants. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the window of the visit of interest. Plasma samples were collected for quantitative analysis of HIV-1 RNA. The Intent-to-Treat Exposed (ITT-E) population consisted of all randomly assigned participants who received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[1]	256 ^[2]		
Units: Percentage of participants				
number (not applicable)	95	96		

Notes:

[1] - ITT-E Population

[2] - ITT-E Population

Statistical analyses

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

Estimates based on Cochran-Mantel Haenszel stratified analysis adjusting for Baseline stratification factors: Age group (< or >=50 years old) and Baseline third agent (PI, NNRTI, INI).

Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Risk difference (RD)
Point estimate	-0.6

Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.3
upper limit	3

Secondary: Changes from Baseline in cluster designation (CD)4+ lymphocyte count at Weeks 24 and 48

End point title	Changes from Baseline in cluster designation (CD)4+ lymphocyte count at Weeks 24 and 48
End point description: Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunological activity of DTG + RPV once daily compared to continuation of CAR. Value obtained at Day 1 was considered as Baseline value. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).	
End point type	Secondary
End point timeframe: Baseline (Day 1), Weeks 24 and 48	

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[3]	256 ^[4]		
Units: Cells per millimeter cube (mm) ³				
arithmetic mean (standard deviation)				
Week 24, n=247, 249	16.2 (± 150.34)	47.4 (± 179.68)		
Week 48, n=239, 245	32.3 (± 149.52)	41.8 (± 185.53)		

Notes:

[3] - ITT-E Population

[4] - ITT-E Population

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with plasma HIV 1 RNA <50 c/mL at Week 24 using snapshot algorithm

End point title	Percentage of participants with plasma HIV 1 RNA <50 c/mL at Week 24 using snapshot algorithm
End point description: Percentage of participants with plasma HIV 1 RNA < 50 c/mL at Week 24 using the FDA snapshot algorithm was assessed to evaluate the antiviral activity of DTG + RPV once daily compared to continuation of CAR. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the window of the visit of interest. Plasma samples were collected for quantitative analysis of HIV-1 RNA.	
End point type	Secondary

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[5]	256 ^[6]		
Units: Percentage of participants				
number (not applicable)	98	96		

Notes:

[5] - ITT-E Population

[6] - ITT-E Population

Statistical analyses

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

Cochran-Mantel Haenszel stratified analysis adjusting for Baseline stratification factors: Age group (< or >=50 years old) and Baseline third agent (PI, NNRTI, INI). No formal non-inferiority margin has been pre-specified for secondary endpoints.

Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Risk difference (RD)
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	4

Secondary: Number of participants with common non-serious adverse event (AE), any serious AE (SAE), AE of maximum toxicity grade 1, 2, 3 or 4 and AE leading to discontinuation (AELD)

End point title	Number of participants with common non-serious adverse event (AE), any serious AE (SAE), AE of maximum toxicity grade 1, 2, 3 or 4 and AE leading to discontinuation (AELD)
-----------------	---

End point description:

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with use of a medicinal product, whether or not considered related to medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention were categorized as SAE. AEs were graded as per Division of Acquired Immunodeficiency Syndrome (DAIDS) grading. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening. Common AEs were those with >5% incidence for either treatment. This summary presents results as reported after all participants completed the Early Switch Phase.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 52

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[7]	256 ^[8]		
Units: Participants				
Common non-serious AE	65	68		
Any SAE	9	12		
Maximum Grade 1 AE	128	122		
Maximum toxicity Grade 2 AE	57	53		
Maximum toxicity Grade 3 AE	11	13		
Maximum toxicity Grade 4 AE	4	2		
AELD	9	2		

Notes:

[7] - Safety Population included all randomized participants who received at least one dose of study drug

[8] - Safety Population included all randomized participants who received at least one dose of study drug

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with maximum post-Baseline emergent chemistry toxicities over 48 weeks

End point title	Number of participants with maximum post-Baseline emergent chemistry toxicities over 48 weeks
-----------------	---

End point description:

Blood samples were collected to evaluate alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), total bilirubin, chloride, creatinine, glucose, potassium, phosphate, sodium, blood urea nitrogen (BUN), total carbon dioxide, lipase, creatine phosphokinase and creatinine clearance. Value obtained at Day 1 was considered as Baseline value. Number of participants who experienced maximum grade toxicity post-Baseline in clinical chemistry over 48 weeks was summarized. Clinical chemistry toxicities were graded using DAIDS grading table for grading severity of adult and pediatric adverse events. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening. For all laboratory parameters, one assessment out of range was sufficient to be considered a chemistry toxicity.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 48 weeks

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[9]	256 ^[10]		
Units: Participants				
Grade 1	95	78		

Grade 2	61	86		
Grade 3	22	23		
Grade 4	5	9		

Notes:

[9] - Safety Population

[10] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with maximum post-Baseline emergent hematology toxicities over 48 weeks

End point title	Number of participants with maximum post-Baseline emergent hematology toxicities over 48 weeks
-----------------	--

End point description:

Blood samples were collected to evaluate hemoglobin, hematocrit, basophils, eosinophils, lymphocytes, monocytes, neutrophils, mean corpuscular volume (MCV), red blood cell (RBC) count, white blood cell (WBC) count and platelet count. Value obtained at Day 1 was considered as Baseline value. Number of participants who experienced maximum grade toxicity post-Baseline in hematology over 48 weeks was summarized. Hematology toxicities were graded using DAIDS grading table for grading severity of adult and pediatric adverse events. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening. For all laboratory parameters, one assessment out of range was sufficient to be considered a hematology toxicity.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 48 weeks

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[11]	256 ^[12]		
Units: Participants				
Grade 1	11	11		
Grade 2	3	2		
Grade 3	3	1		
Grade 4	0	1		

Notes:

[11] - Safety Population

[12] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in high-sensitivity C-reactive protein (hs-CRP) at Week 48

End point title	Mean change from Baseline in high-sensitivity C-reactive protein (hs-CRP) at Week 48
-----------------	--

End point description:

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess hs-CRP. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those

participants with data available at the specified time points were analyzed.

End point type	Secondary
End point timeframe:	
Baseline (Day 1) and Week 48	

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	234 ^[13]	243 ^[14]		
Units: mg/ Liter (L)				
arithmetic mean (standard deviation)	0.11 (± 5.379)	0.15 (± 4.944)		

Notes:

[13] - Safety Population

[14] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in cystatin C at Week 48

End point title	Mean change from Baseline in cystatin C at Week 48
End point description:	
Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess cystatin C Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed.	
End point type	Secondary
End point timeframe:	
Baseline (Day 1) and Week 48	

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	237 ^[15]	245 ^[16]		
Units: mg/L				
arithmetic mean (standard deviation)	0.00 (± 0.113)	-0.01 (± 0.106)		

Notes:

[15] - Safety Population

[16] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in D-Dimer at Week 48

End point title	Mean change from Baseline in D-Dimer at Week 48
-----------------	---

End point description:

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess D-Dimer. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed.

End point type	Secondary
End point timeframe:	
Baseline (Day 1) and Week 48	

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	224 ^[17]	238 ^[18]		
Units: Nanomole/L fibrinogen equivalent units				
arithmetic mean (standard deviation)	-0.02 (± 2.651)	0.02 (± 2.501)		

Notes:

[17] - Safety Population

[18] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in fatty acid binding protein 2 (FABP) and soluble CD14 at Week 48

End point title	Mean change from Baseline in fatty acid binding protein 2 (FABP) and soluble CD14 at Week 48
-----------------	--

End point description:

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess FABP and soluble CD14. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
End point timeframe:	
Baseline (Day 1) and Week 48	

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[19]	256 ^[20]		
Units: Nanogram/milliliter				
arithmetic mean (standard deviation)				
FABP, n=233, 242	-2.79 (± 3.007)	-1.93 (± 2.150)		
Soluble CD14, n=234, 242	379.72 (± 634.053)	754.54 (± 656.462)		

Notes:

[19] - Safety Population

[20] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in Soluble CD163 and oxidized low density lipoprotein (LDL) at Week 48

End point title	Mean change from Baseline in Soluble CD163 and oxidized low density lipoprotein (LDL) at Week 48
-----------------	--

End point description:

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess soluble CD163 and oxidized LDL. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) and Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[21]	256 ^[22]		
Units: Microgram (ug)/Liter				
arithmetic mean (standard deviation)				
Soluble CD163, n=232, 241	50.18 (± 188.772)	54.26 (± 238.900)		
Oxidized LDL, n=234, 242	9.49 (± 745.962)	-41.30 (± 726.014)		

Notes:

[21] - Safety Population

[22] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in retinol binding protein (RBP), serum creatinine and glucose at Week 48

End point title	Mean change from Baseline in retinol binding protein (RBP), serum creatinine and glucose at Week 48
-----------------	---

End point description:

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess RBP, serum creatinine and glucose. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) and Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[23]	256 ^[24]		
Units: mg/deciliter (dL)				
arithmetic mean (standard deviation)				
RBP, n=235, 243	-0.13 (± 1.023)	0.03 (± 0.974)		
Serum creatinine, n=238, 243	0.087 (± 0.1074)	0.011 (± 0.0876)		
Glucose, n=227, 227	0.762 (± 13.6194)	2.492 (± 12.1674)		

Notes:

[23] - Safety Population

[24] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in urine phosphate at Week 48

End point title	Mean change from Baseline in urine phosphate at Week 48
-----------------	---

End point description:

Urine biomarker samples were collected at Baseline (Day 1) and Week 48 to assess urine phosphate. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) and Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	218 ^[25]	224 ^[26]		
Units: Millimoles (mmol)/ L				
arithmetic mean (standard deviation)	-1.079 (± 16.9226)	-1.511 (± 15.8515)		

Notes:

[25] - Safety Population

[26] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in beta-2-microglobulin (B2M) (blood and urine), urine RBP and 25 hydroxy-vitamin D (blood) at Week 48

End point title	Mean change from Baseline in beta-2-microglobulin (B2M) (blood and urine), urine RBP and 25 hydroxy-vitamin D (blood) at Week 48
-----------------	--

End point description:

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess B2M and 25 hydroxy-vitamin D. Urine samples were collected to assess B2M and RBP. Change from Baseline was calculated as value at indicated time point minus Baseline value. For 25 hydroxy-vitamin D, analysis of changes from Baseline was performed on log-transformed data. Results were transformed back via exponential transformation such that treatment comparisons are assessed via odds ratios. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) and Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[27]	256 ^[28]		
Units: Nanomoles/ L				
arithmetic mean (standard deviation)				
B2M, blood, n=233, 241	-15.1452 (± 44.55903)	-4.5995 (± 38.90474)		
25 hydroxy-vitamin D, n=235, 244	-13.9 (± 22.76)	-8.2 (± 24.43)		
Urine B2M, n=89, 96	-128.2045 (± 726.38825)	39.8394 (± 253.43025)		
Urine RBP, n=221, 231	-8.8395 (± 28.83977)	-0.5851 (± 27.56405)		

Notes:

[27] - Safety Population

[28] - Safety Population

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.007 ^[29]
Method	ANCOVA

Notes:

[29] - P-value for interaction between treatment group and baseline third agent (25 hydroxy-vitamin D)

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Estimates are calculated from an ANCOVA model adjusting for Baseline third agent class, age, sex, BMI category, smoking status and baseline biomarker level.	
Comparison groups	DTG + RPV v Current antiretroviral regimen

Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.275 ^[30]
Method	ANCOVA
Parameter estimate	Odds ratio (OR)
Point estimate	0.958
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.888
upper limit	1.034

Notes:

[30] - P value to assess difference between treatment groups (25 hydroxy-vitamin D - NNRTI)

Statistical analysis title	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:

Estimates are calculated from an ANCOVA model adjusting for Baseline third agent class, age, sex, BMI category, smoking status and baseline biomarker level.

Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.112 ^[31]
Method	ANCOVA
Parameter estimate	Odds ratio (OR)
Point estimate	0.902
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.793
upper limit	1.025

Notes:

[31] - P value to assess difference between treatment groups (25 hydroxy-vitamin D - INI)

Statistical analysis title	Statistical Analysis 4
-----------------------------------	------------------------

Statistical analysis description:

Estimates are calculated from an ANCOVA model adjusting for Baseline third agent class, age, sex, BMI category, smoking status and baseline biomarker level.

Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.002 ^[32]
Method	ANCOVA
Parameter estimate	Odds ratio (OR)
Point estimate	0.847

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.763
upper limit	0.942

Notes:

[32] - P value to assess difference between treatment groups (25 hydroxy-vitamin D - PI)

Secondary: Mean change from Baseline in urine albumin/creatinine ratio and urine protein/creatinine ratio at Week 48

End point title	Mean change from Baseline in urine albumin/creatinine ratio and urine protein/creatinine ratio at Week 48
-----------------	---

End point description:

Urine biomarker samples were collected at Baseline (Day 1) and Week 48 to assess urine albumin/creatinine ratio and urine protein/creatinine ratio. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) and Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[33]	256 ^[34]		
Units: Grams (g)/ mol				
arithmetic mean (standard deviation)				
Urine albumin/creatinine ratio, n=166, 171	-1.19 (± 3.916)	-2.59 (± 28.878)		
urine protein/creatinine ratio, n=176, 182	-5.63 (± 17.219)	-1.43 (± 42.832)		

Notes:

[33] - Safety Population

[34] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in bone-specific alkaline phosphatase, procollagen 1 N-terminal propeptide, osteocalcin, Type I Collagen C-Telopeptides and soluble vascular cell adhesion molecule (sVCAM) at Week 48

End point title	Mean change from Baseline in bone-specific alkaline phosphatase, procollagen 1 N-terminal propeptide, osteocalcin, Type I Collagen C-Telopeptides and soluble vascular cell adhesion molecule (sVCAM) at Week 48
-----------------	--

End point description:

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess bone-specific alkaline phosphatase, procollagen 1 N-terminal propeptide, osteocalcin, Type I Collagen C-Telopeptides and sVCAM. Change from Baseline was calculated as value at indicated time point minus Baseline value. For bone-specific alkaline phosphatase, procollagen 1-N-propeptide, osteocalcin and type 1 collagen C-telopeptide, analyses of changes from baseline were performed on log-transformed data. Results were transformed back via exponential transformation such that treatment comparisons are assessed via

odds ratios. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
End point timeframe:	
Baseline (Day 1) and Week 48	

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[35]	256 ^[36]		
Units: ug/ L				
arithmetic mean (standard deviation)				
Bone-specific alkaline phosphatase, n=234, 244	-2.89 (± 4.024)	0.90 (± 4.129)		
Procollagen type 1 N-propeptide, n=234, 242	-9.1 (± 20.34)	-1.4 (± 18.95)		
Osteocalcin, n=233, 242	-4.40 (± 7.605)	-0.68 (± 6.579)		
Type I Collagen C-Telopeptides, n=234, 241	-0.18 (± 0.307)	-0.04 (± 1.160)		
sVCAM, n=234, 243	-2.21 (± 1291.994)	89.07 (± 1239.465)		

Notes:

[35] - Safety Population

[36] - Safety Population

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.001 ^[37]
Method	ANCOVA

Notes:

[37] - P-value for interaction between treatment group and baseline third agent (bone-specific alkaline phosphatase)

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Estimates are calculated from an ANCOVA model adjusting for Baseline third agent class, age, sex, BMI category, smoking status and Baseline biomarker level.	
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[38]
Method	ANCOVA
Parameter estimate	Odds ratio (OR)
Point estimate	0.724

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.679
upper limit	0.772

Notes:

[38] - P value to assess difference between treatment groups (bone-specific alkaline phosphatase - NNRTI)

Statistical analysis title	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:

Estimates are calculated from an ANCOVA model adjusting for Baseline third agent class, age, sex, BMI category, smoking status and Baseline biomarker level.

Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[39]
Method	ANCOVA
Parameter estimate	Odds ratio (OR)
Point estimate	0.825

Confidence interval

level	95 %
sides	2-sided
lower limit	0.742
upper limit	0.918

Notes:

[39] - P value to assess difference between treatment groups (bone-specific alkaline phosphatase - INI)

Statistical analysis title	Statistical Analysis 4
-----------------------------------	------------------------

Statistical analysis description:

Estimates are calculated from an ANCOVA model adjusting for Baseline third agent class, age, sex, BMI category, smoking status and Baseline biomarker level.

Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[40]
Method	ANCOVA
Parameter estimate	Odds ratio (OR)
Point estimate	0.81

Confidence interval

level	95 %
sides	2-sided
lower limit	0.742
upper limit	0.884

Notes:

[40] - P value to assess difference between treatment groups (bone-specific alkaline phosphatase - PI)

Statistical analysis title	Statistical Analysis 5
Comparison groups	DTG + RPV v Current antiretroviral regimen

Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.677 ^[41]
Method	ANCOVA

Notes:

[41] - P-value for interaction between treatment group and Baseline third agent (procollagen type 1-N-propeptide)

Statistical analysis title	Statistical Analysis 6
-----------------------------------	------------------------

Statistical analysis description:

Estimates are calculated from an ANCOVA model adjusting for Baseline third agent class, age, sex, BMI category, smoking status and Baseline biomarker level.

Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[42]
Method	ANCOVA
Parameter estimate	Odds ratio (OR)
Point estimate	0.817
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.774
upper limit	0.863

Notes:

[42] - P value to assess difference between treatment groups (procollagen type 1-N-propeptide)

Statistical analysis title	Statistical Analysis 7
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[43]
Method	ANCOVA

Notes:

[43] - P-value for interaction between treatment group and Baseline third agent (osteocalcin)

Statistical analysis title	Statistical Analysis 8
-----------------------------------	------------------------

Statistical analysis description:

Estimates are calculated from an ANCOVA model adjusting for Baseline third agent class, age, sex, BMI category, smoking status and Baseline biomarker level.

Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[44]
Method	ANCOVA
Parameter estimate	Odds ratio (OR)
Point estimate	0.881

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.823
upper limit	0.943

Notes:

[44] - P value to assess difference between treatment groups (osteocalcin - NNRTI)

Statistical analysis title	Statistical Analysis 9
-----------------------------------	------------------------

Statistical analysis description:

Estimates are calculated from an ANCOVA model adjusting for Baseline third agent class, age, sex, BMI category, smoking status and Baseline biomarker level.

Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.001 ^[45]
Method	ANCOVA
Parameter estimate	Odds ratio (OR)
Point estimate	0.829

Confidence interval

level	95 %
sides	2-sided
lower limit	0.74
upper limit	0.93

Notes:

[45] - P value to assess difference between treatment groups (osteocalcin - INI)

Statistical analysis title	Statistical Analysis 10
-----------------------------------	-------------------------

Statistical analysis description:

Estimates are calculated from an ANCOVA model adjusting for Baseline third agent class, age, sex, BMI category, smoking status and Baseline biomarker level.

Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[46]
Method	ANCOVA
Parameter estimate	Odds ratio (OR)
Point estimate	0.691

Confidence interval

level	95 %
sides	2-sided
lower limit	0.628
upper limit	0.759

Notes:

[46] - P value to assess difference between treatment groups (osteocalcin - PI)

Statistical analysis title	Statistical Analysis 11
Comparison groups	DTG + RPV v Current antiretroviral regimen

Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.782 ^[47]
Method	ANCOVA

Notes:

[47] - P-value for interaction between treatment group and baseline third agent (type 1 collagen cross-linked C-telopeptide)

Statistical analysis title	Statistical Analysis 12
-----------------------------------	-------------------------

Statistical analysis description:

Estimates are calculated from an ANCOVA model adjusting for Baseline third agent class, age, sex, BMI category, smoking status and Baseline biomarker level.

Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[48]
Method	ANCOVA
Parameter estimate	Odds ratio (OR)
Point estimate	0.804
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.742
upper limit	0.872

Notes:

[48] - P value to assess difference between treatment groups (type 1 collagen cross-linked C-telopeptide)

Secondary: Mean change from Baseline in interleukin 6 (IL-6) at Week 48

End point title	Mean change from Baseline in interleukin 6 (IL-6) at Week 48
-----------------	--

End point description:

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess IL-6. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time point were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) and Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	233 ^[49]	243 ^[50]		
Units: Nanograms (ng)/ L				
arithmetic mean (standard deviation)	0.17 (± 2.736)	-0.18 (± 2.944)		

Notes:

[49] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in insulin resistance based on homeostasis model assessment of insulin resistance (HOMA-IR) at Week 48

End point title	Mean change from Baseline in insulin resistance based on homeostasis model assessment of insulin resistance (HOMA-IR) at Week 48
-----------------	--

End point description:

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess insulin resistance. Change from Baseline was calculated as value at indicated time point minus Baseline value. The homeostatic model assessment (HOMA) of insulin resistance (HOMA-IR) index, the product of basal glucose and insulin levels divided by 22.5 (1,2), is regarded as a simple, inexpensive, and reliable surrogate measure of insulin resistance. Only those participants with data available at the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) and Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	229 ^[51]	237 ^[52]		
Units: HOMA-IR Score				
arithmetic mean (standard deviation)	-0.30 (± 5.740)	0.51 (± 3.530)		

Notes:

[51] - Safety Population

[52] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in fasting lipids at Weeks 24 and 48

End point title	Mean change from Baseline in fasting lipids at Weeks 24 and 48
-----------------	--

End point description:

Blood samples were collected at Baseline (Day 1), Week 24 and Week 48 to assess fasting lipids which included total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol and triglycerides. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), Week 24 and Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[53]	256 ^[54]		
Units: mmol/ L				
arithmetic mean (standard deviation)				
Total cholesterol, Week 24, n=228, 223	0.076 (± 0.8398)	0.061 (± 0.7368)		
Total cholesterol, Week 48, n=221, 218	0.089 (± 0.8488)	0.064 (± 0.7197)		
LDL cholesterol calculation, Week 24, n=224, 217	0.165 (± 0.7065)	0.103 (± 0.6503)		
LDL cholesterol calculation, Week 48, n=215, 211	0.108 (± 0.7178)	0.029 (± 0.6134)		
HDL cholesterol direct, Week 24, n=228, 223	-0.030 (± 0.2601)	-0.044 (± 0.2394)		
HDL cholesterol direct, Week 48, n=221, 218	0.023 (± 0.2757)	0.018 (± 0.2722)		
Triglycerides, Week 24, n=228, 223	-0.154 (± 0.7324)	-0.001 (± 0.7712)		
Triglycerides, Week 48, n=221, 218	-0.093 (± 0.9767)	0.046 (± 0.8274)		

Notes:

[53] - Safety Population

[54] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with genotypic resistance- Early switch Phase

End point title	Number of participants with genotypic resistance- Early switch Phase
-----------------	--

End point description:

Plasma samples were collected for drug resistance testing. Confirmed Virologic Withdrawal (CVW) resistance Population comprised of all participants in the ITT-E Population who met confirmed CVW through the end of visit window (Week 48, Week 100 or Week 148) and had available on-treatment genotypic resistance data at the time CVW criterion was met. Genotypic Resistance data for the following drugs (Rilpivirine [RPV], Dolutegravir [DTG], Emtricitabine [FTC], Tenofovir [TDF], Darunavir/r [DRV/r]) in participants Meeting CVW criteria has been presented. 99999 indicates data was not applicable as the drugs were not received. Genotypic resistance data is only shown for drugs received for Participants Meeting Confirmed Virologic Withdrawal Criteria

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[55]	1 ^[56]		
Units: Participants				
NNRTI, RPV, Susceptible	1	99999		
NNRTI, RPV, Potential low-level resistance	0	99999		
NNRTI, RPV, Low-level resistance	0	99999		
NNRTI, RPV, Intermediate resistance	0	99999		
NNRTI, RPV, High-level resistance	0	99999		
INI, DTG, Susceptible	1	99999		
INI, DTG, Potential low-level resistance	0	99999		
INI, DTG, Low-level resistance	0	99999		
INI, DTG, Intermediate resistance	0	99999		
INI, DTG, High-level resistance	0	99999		
NRTI, FTC, Susceptible	99999	1		
NRTI, FTC, Potential low-level resistance	99999	0		
NRTI, FTC, Low-level resistance	99999	0		
NRTI, FTC, Intermediate resistance	99999	0		
NRTI, FTC, High-level resistance	99999	0		
NRTI, TDF, Susceptible	99999	1		
NRTI, TDF, Potential low-level resistance	99999	0		
NRTI, TDF, Low-level resistance	99999	0		
NRTI, TDF, Intermediate resistance	99999	0		
NRTI, TDF, High-level resistance	99999	0		
PI, DRV/r, Susceptible	99999	1		
PI, DRV/r, Potential low-level resistance	99999	0		
PI, DRV/r, Low-level resistance	99999	0		
PI, DRV/r, Intermediate resistance	99999	0		
PI, DRV/r, High-level resistance	99999	0		

Notes:

[55] - CVW Resistance Population

[56] - CVW Resistance Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with genotypic resistance-DTG+RPV early switch group through Early and Late Switch Phase

End point title	Number of participants with genotypic resistance-DTG+RPV early switch group through Early and Late Switch Phase ^[57]
-----------------	---

End point description:

Plasma samples were collected for drug resistance testing. Genotypic Resistance data for the following drugs (DTG, Elvitegravir [EVG], Raltegravir [RAL], Delavirdine [DLV], Efavirenz [EFV], Etravirine [ETR], Nevirapine [NVP], RPV, Lamivudine [3TC], Abacavir [ABC], FTC, TDF, Zidovudine [ZDV], Stavudine [d4T], Didanosine [ddI], Atazanavir/r [ATV/r], DRV/r, Fosamprenavir/r [FPV/r], Indinavir/r [IDV/r], Lopinavir/r [LPV/r], Nelfinavir [NFV], Ritonavir [RTV], Saquinavir/r [SQV/r], Tipranavir/r [TPV/r]) in participants Meeting Confirmed Virologic Withdrawal Criteria has been presented.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 148

Notes:

[57] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period.

End point values	DTG + RPV			
Subject group type	Reporting group			
Number of subjects analysed	5 ^[58]			
Units: Participants				
INI, DTG, Susceptible	5			
INI, DTG, Potential low-level resistance	0			
INI, DTG, Low-level resistance	0			
INI, DTG, Intermediate resistance	0			
INI, DTG, High-level resistance	0			
INI, EVG, Susceptible	4			
INI, EVG, Potential low-level resistance	1			
INI, EVG, Low-level resistance	0			
INI, EVG, Intermediate resistance	0			
INI, EVG, High-level resistance	0			
INI, RAL, Susceptible	4			
INI, RAL, Potential low-level resistance	1			
INI, RAL, Low-level resistance	0			
INI, RAL, Intermediate resistance	0			
INI, RAL, High-level resistance	0			
NNRTI, DLV, Susceptible	5			
NNRTI, DLV, Potential low-level resistance	0			
NNRTI, DLV, Low-level resistance	0			
NNRTI, DLV, Intermediate resistance	0			
NNRTI, DLV, High-level resistance	0			
NNRTI, EFV, Susceptible	3			
NNRTI, EFV, Potential low-level resistance	0			
NNRTI, EFV, Low-level resistance	0			
NNRTI, EFV, Intermediate resistance	1			
NNRTI, EFV, High-level resistance	1			
NNRTI, ETR, Susceptible	3			
NNRTI, ETR, Potential low-level resistance	1			
NNRTI, ETR, Low-level resistance	0			
NNRTI, ETR, Intermediate resistance	1			
NNRTI, ETR, High-level resistance	0			
NNRTI, NVP, Susceptible	3			
NNRTI, NVP, Potential low-level resistance	0			
NNRTI, NVP, Low-level resistance	0			
NNRTI, NVP, Intermediate resistance	0			
NNRTI, NVP, High-level resistance	2			
NNRTI, RPV, Susceptible	3			
NNRTI, RPV, Potential low-level resistance	0			
NNRTI, RPV, Low-level resistance	1			

NNRTI, RPV, Intermediate resistance	0			
NNRTI, RPV, High-level resistance	1			
NRTI, 3TC, Susceptible	5			
NRTI, 3TC, Potential low-level resistance	0			
NRTI, 3TC, Low-level resistance	0			
NRTI, 3TC, Intermediate resistance	0			
NRTI, 3TC, High-level resistance	0			
NRTI, ABC, Susceptible	5			
NRTI, ABC, Potential low-level resistance	0			
NRTI, ABC, Low-level resistance	0			
NRTI, ABC, Intermediate resistance	0			
NRTI, ABC, High-level resistance	0			
NRTI, FTC, Susceptible	5			
NRTI, FTC, Potential low-level resistance	0			
NRTI, FTC, Low-level resistance	0			
NRTI, FTC, Intermediate resistance	0			
NRTI, FTC, High-level resistance	0			
NRTI, TDF, Susceptible	5			
NRTI, TDF, Potential low-level resistance	0			
NRTI, TDF, Low-level resistance	0			
NRTI, TDF, Intermediate resistance	0			
NRTI, TDF, High-level resistance	0			
NRTI, ZDV, Susceptible	4			
NRTI, ZDV, Potential low-level resistance	1			
NRTI, ZDV, Low-level resistance	0			
NRTI, ZDV, Intermediate resistance	0			
NRTI, ZDV, High-level resistance	0			
NRTI, d4T, Susceptible	4			
NRTI, d4T, Potential low-level resistance	1			
NRTI, d4T, Low-level resistance	0			
NRTI, d4T, Intermediate resistance	0			
NRTI, d4T, High-level resistance	0			
NRTI, ddI, Susceptible	5			
NRTI, ddI, Potential low-level resistance	0			
NRTI, ddI, Low-level resistance	0			
NRTI, ddI, Intermediate resistance	0			
NRTI, ddI, High-level resistance	0			
PI, ATV/r, Susceptible	5			
PI, ATV/r, Potential low-level resistance	0			
PI, ATV/r, Low-level resistance	0			
PI, ATV/r, Intermediate resistance	0			
PI, ATV/r, High-level resistance	0			
PI, DRV/r, Susceptible	5			
PI, DRV/r, Potential low-level resistance	0			
PI, DRV/r, Low-level resistance	0			
PI, DRV/r, Intermediate resistance	0			
PI, DRV/r, High-level resistance	0			
PI, FPV/r, Susceptible	5			
PI, FPV/r, Potential low-level resistance	0			
PI, FPV/r, Low-level resistance	0			

PI, FPV/r, Intermediate resistance	0			
PI, FPV/r, High-level resistance	0			
PI, IDV/r, Susceptible	5			
PI, IDV/r, Potential low-level resistance	0			
PI, IDV/r, Low-level resistance	0			
PI, IDV/r, Intermediate resistance	0			
PI, IDV/r, High-level resistance	0			
PI, LPV/r, Susceptible	5			
PI, LPV/r, Potential low-level resistance	0			
PI, LPV/r, Low-level resistance	0			
PI, LPV/r, Intermediate resistance	0			
PI, LPV/r, High-level resistance	0			
PI, NFV, Susceptible	5			
PI, NFV, Potential low-level resistance	0			
PI, NFV, Low-level resistance	0			
PI, NFV, Intermediate resistance	0			
PI, NFV, High-level resistance	0			
PI, RTV, Susceptible	5			
PI, RTV, Potential low-level resistance	0			
PI, RTV, Low-level resistance	0			
PI, RTV, Intermediate resistance	0			
PI, RTV, High-level resistance	0			
PI, SQV/r, Susceptible	5			
PI, SQV/r, Potential low-level resistance	0			
PI, SQV/r, Low-level resistance	0			
PI, SQV/r, Intermediate resistance	0			
PI, SQV/r, High-level resistance	0			
PI, TPV/r, Susceptible	5			
PI, TPV/r, Potential low-level resistance	0			
PI, TPV/r, Low-level resistance	0			
PI, TPV/r, Intermediate resistance	0			
PI, TPV/r, High-level resistance	0			

Notes:

[58] - CVW resistance Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with genotypic resistance -CAR Late Switch group through Late Switch Phase

End point title	Number of participants with genotypic resistance -CAR Late Switch group through Late Switch Phase
-----------------	---

End point description:

Plasma samples were collected for drug resistance testing. Late Switch (LS) CVW resistance Population comprised of all participants in the LS-ITT-E Population who met CVW through the end of visit window (Week 48, Week 100 or Week 148) and had available on-treatment genotypic resistance data at the time CVW criterion was met. Genotypic Resistance data for the following drugs (DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r) in participants Meeting CVW Criteria has been presented. Only those participants with data available at the specified time point were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Post-LS Baseline (Week 52) up to Week 148

End point values	Current antiretroviral regimen			
Subject group type	Reporting group			
Number of subjects analysed	1 ^[59]			
Units: Participants				
INI, DTG, Susceptible	1			
INI, DTG, Potential low-level resistance	0			
INI, DTG, Low-level resistance	0			
INI, DTG, Intermediate resistance	0			
INI, DTG, High-level resistance	0			
INI, EVG, Susceptible	1			
INI, EVG, Potential low-level resistance	0			
INI, EVG, Low-level resistance	0			
INI, EVG, Intermediate resistance	0			
INI, EVG, High-level resistance	0			
INI, RAL, Susceptible	0			
INI, RAL, Potential low-level resistance	0			
INI, RAL, Low-level resistance	0			
INI, RAL, Intermediate resistance	0			
INI, RAL, High-level resistance	0			
NNRTI, DLV, Susceptible	1			
NNRTI, DLV, Potential low-level resistance	0			
NNRTI, DLV, Low-level resistance	0			
NNRTI, DLV, Intermediate resistance	0			
NNRTI, DLV, High-level resistance	0			
NNRTI, EFV, Susceptible	0			
NNRTI, EFV, Potential low-level resistance	1			
NNRTI, EFV, Low-level resistance	0			
NNRTI, EFV, Intermediate resistance	0			
NNRTI, EFV, High-level resistance	0			
NNRTI, ETR, Susceptible	0			
NNRTI, ETR, Potential low-level resistance	1			
NNRTI, ETR, Low-level resistance	0			
NNRTI, ETR, Intermediate resistance	0			
NNRTI, ETR, High-level resistance	0			
NNRTI, NVP, Susceptible	0			
NNRTI, NVP, Potential low-level resistance	1			
NNRTI, NVP, Low-level resistance	0			
NNRTI, NVP, Intermediate resistance	0			
NNRTI, NVP, High-level resistance	0			
NNRTI, RPV, Susceptible	0			
NNRTI, RPV, Potential low-level resistance	1			

NNRTI, RPV, Low-level resistance	0			
NNRTI, RPV, Intermediate resistance	0			
NNRTI, RPV, High-level resistance	0			
NRTI, 3TC, Susceptible	1			
NRTI, 3TC, Potential low-level resistance	0			
NRTI, 3TC, Low-level resistance	0			
NRTI, 3TC, Intermediate resistance	0			
NRTI, 3TC, High-level resistance	0			
NRTI, ABC, Susceptible	1			
NRTI, ABC, Potential low-level resistance	0			
NRTI, ABC, Low-level resistance	0			
NRTI, ABC, Intermediate resistance	0			
NRTI, ABC, High-level resistance	0			
NRTI, FTC, Susceptible	1			
NRTI, FTC, Potential low-level resistance	0			
NRTI, FTC, Low-level resistance	0			
NRTI, FTC, Intermediate resistance	0			
NRTI, FTC, High-level resistance	0			
NRTI, TDF, Susceptible	1			
NRTI, TDF, Potential low-level resistance	0			
NRTI, TDF, Low-level resistance	0			
NRTI, TDF, Intermediate resistance	0			
NRTI, TDF, High-level resistance	0			
NRTI, ZDV, Susceptible	1			
NRTI, ZDV, Potential low-level resistance	0			
NRTI, ZDV, Low-level resistance	0			
NRTI, ZDV, Intermediate resistance	0			
NRTI, ZDV, High-level resistance	0			
NRTI, d4T, Susceptible	1			
NRTI, d4T, Potential low-level resistance	0			
NRTI, d4T, Low-level resistance	0			
NRTI, d4T, Intermediate resistance	0			
NRTI, d4T, High-level resistance	0			
NRTI, ddI, Susceptible	1			
NRTI, ddI, Potential low-level resistance	0			
NRTI, ddI, Low-level resistance	0			
NRTI, ddI, Intermediate resistance	0			
NRTI, ddI, High-level resistance	0			
PI, ATV/r, Susceptible	1			
PI, ATV/r, Potential low-level resistance	0			
PI, ATV/r, Low-level resistance	0			
PI, ATV/r, Intermediate resistance	0			
PI, ATV/r, High-level resistance	0			
PI, DRV/r, Susceptible	1			
PI, DRV/r, Potential low-level resistance	0			
PI, DRV/r, Low-level resistance	0			
PI, DRV/r, Intermediate resistance	0			
PI, DRV/r, High-level resistance	0			
PI, FPV/r, Susceptible	1			
PI, FPV/r, Potential low-level resistance	0			

PI, FPV/r, Low-level resistance	0			
PI, FPV/r, Intermediate resistance	0			
PI, FPV/r, High-level resistance	0			
PI, IDV/r, Susceptible	1			
PI, IDV/r, Potential low-level resistance	0			
PI, IDV/r, Low-level resistance	0			
PI, IDV/r, Intermediate resistance	0			
PI, IDV/r, High-level resistance	0			
PI, LPV/r, Susceptible	1			
PI, LPV/r, Potential low-level resistance	0			
PI, LPV/r, Low-level resistance	0			
PI, LPV/r, Intermediate resistance	0			
PI, LPV/r, High-level resistance	0			
PI, NFV, Susceptible	1			
PI, NFV, Potential low-level resistance	0			
PI, NFV, Low-level resistance	0			
PI, NFV, Intermediate resistance	0			
PI, NFV, High-level resistance	0			
PI, RTV, Susceptible	1			
PI, RTV, Potential low-level resistance	0			
PI, RTV, Low-level resistance	0			
PI, RTV, Intermediate resistance	0			
PI, RTV, High-level resistance	0			
PI, SQV/r, Susceptible	1			
PI, SQV/r, Potential low-level resistance	0			
PI, SQV/r, Low-level resistance	0			
PI, SQV/r, Intermediate resistance	0			
PI, SQV/r, High-level resistance	0			
PI, TPV/r, Susceptible	1			
PI, TPV/r, Potential low-level resistance	0			
PI, TPV/r, Low-level resistance	0			
PI, TPV/r, Intermediate resistance	0			
PI, TPV/r, High-level resistance	0			

Notes:

[59] - LS CVW resistance Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with phenotypic resistance-Early switch Phase

End point title	Number of participants with phenotypic resistance-Early switch Phase
-----------------	--

End point description:

Plasma samples were collected for drug resistance testing. Phenotypic Resistance data for the following drugs (DTG, RAL, EVG, RPV, ETR, 3TC, ABC, FTC, TDF, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, SQV/r, TPV/r) in participants Meeting CVW Criteria has been presented.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[60]	1 ^[61]		
Units: Participants				
INI, DTG, Resistant	0	0		
INI, DTG, Partially Sensitive	0	0		
INI, DTG, Sensitive	1	1		
INI, EVG, Resistant	0	0		
INI, EVG, Sensitive	1	1		
INI, RAL, Resistant	0	0		
INI, RAL, Sensitive	1	1		
NNRTI, DLV, Resistant	0	0		
NNRTI, DLV, Sensitive	1	1		
NNRTI, EFV, Resistant	0	0		
NNRTI, EFV, Sensitive	1	1		
NNRTI, ETR, Resistant	0	0		
NNRTI, ETR, Partially Sensitive	0	0		
NNRTI, ETR, Sensitive	1	1		
NNRTI, NVP, Resistant	0	0		
NNRTI, NVP, Sensitive	1	1		
NNRTI, RPV, Resistant	0	0		
NNRTI, RPV, Sensitive	1	1		
NRTI, 3TC, Resistant	0	0		
NRTI, 3TC, Sensitive	1	1		
NRTI, ABC, Resistant	0	0		
NRTI, ABC, Partially Sensitive	0	0		
NRTI, ABC, Sensitive	1	1		
NRTI, FTC, Resistant	0	0		
NRTI, FTC, Sensitive	1	1		
NRTI, TDF, Resistant	0	0		
NRTI, TDF, Partially Sensitive	0	0		
NRTI, TDF, Sensitive	1	1		
NRTI, ZDV, Resistant	0	0		
NRTI, ZDV, Sensitive	1	1		
NRTI, d4T, Resistant	0	0		
NRTI, d4T, Sensitive	1	1		
NRTI, ddI, Resistant	0	0		
NRTI, ddI, Partially Sensitive	0	0		
NRTI, ddI, Sensitive	1	1		
PI, ATV/r, Resistant	0	0		
PI, ATV/r, Sensitive	1	1		
PI, DRV/r, Resistant	0	0		
PI, DRV/r, Partially Sensitive	0	0		
PI, DRV/r, Sensitive	1	1		
PI, FPV/r, Resistant	0	0		
PI, FPV/r, Partially Sensitive	0	0		

PI, FPV/r, Sensitive	1	1		
PI, IDV/r, Resistant	0	0		
PI, IDV/r, Sensitive	1	1		
PI, LPV/r, Resistant	0	0		
PI, LPV/r, Partially Sensitive	0	0		
PI, LPV/r, Sensitive	1	1		
PI, NFV, Resistant	0	0		
PI, NFV, Sensitive	1	1		
PI, RTV, Resistant	0	0		
PI, RTV, Sensitive	1	1		
PI, SQV/r, Resistant	0	0		
PI, SQV/r, Partially Sensitive	0	0		
PI, SQV/r, Sensitive	1	1		
PI, TPV/r, Resistant	0	0		
PI, TPV/r, Partially Sensitive	0	0		
PI, TPV/r, Sensitive	1	1		

Notes:

[60] - CVW Resistance Population

[61] - CVW Resistance Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with phenotypic resistance-DTG+RPV early switch group through Early and Late Switch Phase

End point title	Number of participants with phenotypic resistance-DTG+RPV early switch group through Early and Late Switch Phase ^[62]
-----------------	--

End point description:

Plasma samples were collected for drug resistance testing. Phenotypic Resistance data for the following drugs (DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r) in participants Meeting CVW Criteria has been presented.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 148

Notes:

[62] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period.

End point values	DTG + RPV			
Subject group type	Reporting group			
Number of subjects analysed	5 ^[63]			
Units: Participants				
INI, DTG, Resistant	0			
INI, DTG, Partially Sensitive	0			
INI, DTG, Sensitive	5			
INI, EVG, Resistant	0			
INI, EVG, Partially Sensitive	0			
INI, EVG, Sensitive	5			
INI, RAL, Resistant	0			
INI, RAL, Partially Sensitive	0			

INI, RAL, Sensitive	5			
NNRTI, DLV, Resistant	1			
NNRTI, DLV, Partially Sensitive	0			
NNRTI, DLV, Sensitive	4			
NNRTI, EFV, Resistant	1			
NNRTI, EFV, Partially Sensitive	0			
NNRTI, EFV, Sensitive	4			
NNRTI, ETR, Resistant	0			
NNRTI, ETR, Partially Sensitive	1			
NNRTI, ETR, Sensitive	4			
NNRTI, NVP, Resistant	1			
NNRTI, NVP, Partially Sensitive	0			
NNRTI, NVP, Sensitive	4			
NNRTI, RPV, Resistant	1			
NNRTI, RPV, Partially Sensitive	0			
NNRTI, RPV, Sensitive	4			
NRTI, 3TC, Resistant	0			
NRTI, 3TC, Partially Sensitive	0			
NRTI, 3TC, Sensitive	5			
NRTI, ABC, Resistant	0			
NRTI, ABC, Partially Sensitive	0			
NRTI, ABC, Sensitive	5			
NRTI, FTC, Resistant	0			
NRTI, FTC, Partially Sensitive	0			
NRTI, FTC, Sensitive	5			
NRTI, TDF, Resistant	0			
NRTI, TDF, Partially Sensitive	0			
NRTI, TDF, Sensitive	5			
NRTI, ZDV, Resistant	0			
NRTI, ZDV, Partially Sensitive	0			
NRTI, ZDV, Sensitive	5			
NRTI, d4T, Resistant	0			
NRTI, d4T, Partially Sensitive	0			
NRTI, d4T, Sensitive	5			
NRTI, ddI, Resistant	0			
NRTI, ddI, Partially Sensitive	0			
NRTI, ddI, Sensitive	5			
PI, ATV/r, Resistant	0			
PI, ATV/r, Partially Sensitive	0			
PI, ATV/r, Sensitive	5			
PI, DRV/r, Resistant	0			
PI, DRV/r, Partially Sensitive	0			
PI, DRV/r, Sensitive	5			
PI, FPV/r, Resistant	0			
PI, FPV/r, Partially Sensitive	0			
PI, FPV/r, Sensitive	5			
PI, IDV/r, Resistant	0			
PI, IDV/r, Partially Sensitive	0			
PI, IDV/r, Sensitive	5			
PI, LPV/r, Resistant	0			
PI, LPV/r, Partially Sensitive	0			
PI, LPV/r, Sensitive	5			

PI, NFV, Resistant	0			
PI, NFV, Partially Sensitive	0			
PI, NFV, Sensitive	5			
PI, RTV, Resistant	0			
PI, RTV, Partially Sensitive	0			
PI, RTV, Sensitive	5			
PI, SQV/r, Resistant	0			
PI, SQV/r, Partially Sensitive	0			
PI, SQV/r, Sensitive	5			
PI, TPV/r, Resistant	0			
PI, TPV/r, Partially Sensitive	0			
PI, TPV/r, Sensitive	5			

Notes:

[63] - CVW resistance Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with phenotypic resistance-CAR Late Switch group through Late Switch Phase

End point title	Number of participants with phenotypic resistance-CAR Late Switch group through Late Switch Phase
-----------------	---

End point description:

Plasma samples were collected for drug resistance testing. Phenotypic Resistance data for the following drugs (DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r) in participants Meeting CVW Criteria has been presented. Only those participants with data available at the specified time point were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Post-LS Baseline (Week 52) up to Week 148

End point values	Current antiretroviral regimen			
Subject group type	Reporting group			
Number of subjects analysed	1 ^[64]			
Units: Participants				
NNRTI, DLV, Resistant	1			
NNRTI, DLV, Partially Sensitive	0			
NNRTI, DLV, Sensitive	0			
NNRTI, EFV, Resistant	1			
NNRTI, EFV, Partially Sensitive	0			
NNRTI, EFV, Sensitive	0			
NNRTI, ETR, Resistant	0			
NNRTI, ETR, Partially Sensitive	0			
NNRTI, ETR, Sensitive	1			
NNRTI, NVP, Resistant	1			
NNRTI, NVP, Partially Sensitive	0			
NNRTI, NVP, Sensitive	0			

NNRTI, RPV, Resistant	0			
NNRTI, RPV, Partially Sensitive	0			
NNRTI, RPV, Sensitive	1			
NRTI, 3TC, Resistant	0			
NRTI, 3TC, Partially Sensitive	0			
NRTI, 3TC, Sensitive	1			
NRTI, ABC, Resistant	0			
NRTI, ABC, Partially Sensitive	0			
NRTI, ABC, Sensitive	1			
NRTI, FTC, Resistant	0			
NRTI, FTC, Partially Sensitive	0			
NRTI, FTC, Sensitive	1			
NRTI, TDF, Resistant	0			
NRTI, TDF, Partially Sensitive	0			
NRTI, TDF, Sensitive	1			
NRTI, ZDV, Resistant	0			
NRTI, ZDV, Partially Sensitive	0			
NRTI, ZDV, Sensitive	1			
NRTI, d4T, Resistant	0			
NRTI, d4T, Partially Sensitive	0			
NRTI, d4T, Sensitive	1			
NRTI, ddI, Resistant	0			
NRTI, ddI, Partially Sensitive	0			
NRTI, ddI, Sensitive	1			
PI, ATV/r, Resistant	0			
PI, ATV/r, Partially Sensitive	0			
PI, ATV/r, Sensitive	1			
PI, DRV/r, Resistant	0			
PI, DRV/r, Partially Sensitive	0			
PI, DRV/r, Sensitive	1			
PI, FPV/r, Resistant	0			
PI, FPV/r, Partially Sensitive	0			
PI, FPV/r, Sensitive	1			
PI, IDV/r, Resistant	0			
PI, IDV/r, Partially Sensitive	0			
PI, IDV/r, Sensitive	1			
PI, LPV/r, Resistant	0			
PI, LPV/r, Partially Sensitive	0			
PI, LPV/r, Sensitive	1			
PI, NFV, Resistant	0			
PI, NFV, Partially Sensitive	0			
PI, NFV, Sensitive	1			
PI, RTV, Resistant	0			
PI, RTV, Partially Sensitive	0			
PI, RTV, Sensitive	1			
PI, SQV/r, Resistant	0			
PI, SQV/r, Partially Sensitive	0			
PI, SQV/r, Sensitive	1			
PI, TPV/r, Resistant	0			
PI, TPV/r, Partially Sensitive	0			
PI, TPV/r, Sensitive	1			

Notes:

[64] - LS CVW resistance Population

Statistical analyses

No statistical analyses for this end point

Secondary: Pre-dose concentrations of DTG and RPV at Weeks 4, 24, 48, 56, 76 and 100 in participants switching to DTG + RPV -DTG+RPV early switch group through Early and Late Switch Phase

End point title	Pre-dose concentrations of DTG and RPV at Weeks 4, 24, 48, 56, 76 and 100 in participants switching to DTG + RPV - DTG+RPV early switch group through Early and Late Switch Phase
-----------------	---

End point description:

Two separate blood samples for DTG and RPV were collected pre-dose at Weeks 4, 24, 48, 56, 76, and 100. Pre-dose concentrations of DTG and RPV at Weeks 4, 24, 48, 56, 76 and 100 is summarized for the participants switching to DTG + RPV in the early + late switch phase. Pharmacokinetic (PK) Parameter Population consisted of all participants who received DTG +RPV and provided at least one evaluable estimate of predose concentration (C0). Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose at Week 4, 24, 48, 56, 76 and 100

End point values	DTG 50 mg PK Parameter Population	RPV 25 mg PK Parameter Population		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	243 ^[65]	243 ^[66]		
Units: ug/ L				
arithmetic mean (standard deviation)				
Week 4, n=130, 130	1581.06 (± 1146.860)	92.05 (± 138.288)		
Week 24, n=210, 210	1835.68 (± 1120.539)	87.88 (± 39.141)		
Week 48, n=215, 211	1915.11 (± 1304.238)	95.18 (± 48.228)		
Week 56, n=204, 204	1872.65 (± 1173.815)	95.38 (± 53.602)		
Week 76, n=194,194	1711.83 (± 1092.143)	88.10 (± 42.250)		
Week 100, n=203, 203	1854.17 (± 1197.958)	92.38 (± 44.604)		

Notes:

[65] - PK Parameter Population

[66] - PK Parameter Population

Statistical analyses

Secondary: Pre-dose concentrations of DTG and RPV at Weeks 56, 76 and 100 in participants switching to DTG+RPV - CAR Late Switch group through Late Switch Phase

End point title	Pre-dose concentrations of DTG and RPV at Weeks 56, 76 and 100 in participants switching to DTG+RPV - CAR Late Switch group through Late Switch Phase
-----------------	---

End point description:

Two separate blood samples for DTG and RPV were collected pre-dose at Weeks 56, 76, and 100. Pre-dose concentrations of DTG and RPV at Weeks 56, 76 and 100 is summarized for the participants switching to DTG + RPV in the late switch phase. LS PK Parameter Population comprised of all participants who were randomized to CAR and received DTG + RPV in the Late Switch Phase and provided at least one evaluable estimate of Pre-dose concentration. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose at Weeks 56, 76 and 100

End point values	CAR-DTG 50 mg LS PK Parameter Population	CAR-RPV 25 mg LS PK Parameter Population		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	225 ^[67]	225 ^[68]		
Units: ug/ L				
arithmetic mean (standard deviation)				
Week 56, n=198, 198	1738.55 (± 1329.931)	84.14 (± 47.290)		
Week 76, n=192, 192	1800.39 (± 1162.370)	97.79 (± 52.532)		
Week 100, n=192, 191	1907.20 (± 1235.676)	101.93 (± 63.296)		

Notes:

[67] - LS PK Parameter Population

[68] - LS PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Pre-dose concentrations of DTG and RPV at Weeks 2, 4 and 8 in the first 20 participants who switch from efavirenz (EFV) or nevirapine (NVP) to DTG + RPV

End point title	Pre-dose concentrations of DTG and RPV at Weeks 2, 4 and 8 in the first 20 participants who switch from efavirenz (EFV) or nevirapine (NVP) to DTG + RPV
-----------------	--

End point description:

Two blood samples were collected pre-dose for DTG and RPV at Weeks 2, 4 and 8 only for the first 20 participants who switch from EFV or NVP to DTG + RPV. One blood sample was collected pre-dose for EFV or NVP at Week 2 for the first 20 participants who switch from EFV or NVP to DTG + RPV. PK Parameter NNRTI Subset Extra Sampling Population consisted of the first approximately 20 participants in the PK Parameter NNRTI Subset population who have extra PK samples at weeks 2, 4 and 8. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose at Week 2, 4 and 8

End point values	DTG 50 mg PK Parameter NNRTI Subset	RPV 25 mg PK Parameter NNRTI Subset		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	26 ^[69]	26 ^[70]		
Units: ug/ L				
arithmetic mean (standard deviation)				
Week 2, n=16, 15	821.25 (± 574.607)	65.360 (± 31.2965)		
Week 4, n=19, 19	994.00 (± 581.201)	67.374 (± 27.5663)		
Week 8, n=19, 19	1561.34 (± 1096.381)	77.416 (± 37.7129)		

Notes:

[69] - PK Parameter NNRTI Subset extra sampling Population

[70] - PK Parameter NNRTI Subset extra sampling Population

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with plasma HIV 1 RNA <50 c/mL at Week 48 using snapshot algorithm by Baseline third agent treatment class

End point title	Percentage of participants with plasma HIV 1 RNA <50 c/mL at Week 48 using snapshot algorithm by Baseline third agent treatment class
-----------------	---

End point description:

Percentage of participants with plasma HIV 1 RNA < 50 c/mL at Week 48 using the FDA snapshot algorithm was assessed by Baseline third agent class to assess the impact of Baseline third agent class (INI, NNRTI, or PI) on efficacy of DTG +RPV compared to continuation of CAR. Plasma samples were collected for quantitative analysis of HIV-1 RNA. The analysis was done using Cochran-Mantel Haenszel test stratified by current antiretroviral third-agent class and age group. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[71]	256 ^[72]		
Units: Percentage of participants				
number (not applicable)				
NNRTI, n=131, 134	95	98		
INI, n=46, 48	98	96		
PI, n=75, 74	95	92		

Notes:

[71] - ITT-E Population

[72] - ITT-E Population

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.317 ^[73]
Method	Chi-squared corrected

Notes:

[73] - One-sided p-value from weighted least squares chi-squared statistic. A p-value ≤ 0.10 was used to indicate statistically significant evidence of heterogeneity in the difference in proportions across levels of each analysis strata.

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
NNRTI: No formal non-inferiority margin has been pre-specified for secondary endpoints.	
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Risk difference (RD)
Point estimate	-3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.7
upper limit	1.5

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
INI: No formal non-inferiority margin has been pre-specified for secondary endpoints.	
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Risk difference (RD)
Point estimate	2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.1
upper limit	9

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
PI: No formal non-inferiority margin has been pre-specified for secondary endpoints.	
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Risk difference (RD)
Point estimate	2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.3
upper limit	10.8

Secondary: Changes from Baseline in cluster designation (CD)4+ lymphocyte count at Week 48 by Baseline third agent treatment class

End point title	Changes from Baseline in cluster designation (CD)4+ lymphocyte count at Week 48 by Baseline third agent treatment class
-----------------	---

End point description:

Blood samples were collected and CD4 cell count assessment by flow cytometry was carried out to assess the impact of Baseline third agent class (INI, NNRTI, or PI) on efficacy, safety and tolerability of DTG +RPV compared to continuation of CAR. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) and Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[74]	256 ^[75]		
Units: Cells per mm ³				
arithmetic mean (standard deviation)				
NNRTI, n=124, 130	47.9 (± 142.90)	25.0 (± 151.27)		
INI, n=45, 46	19.9 (± 148.63)	39.9 (± 200.38)		
PI, n=70, 69	12.5 (± 160.27)	74.7 (± 227.78)		

Notes:

[74] - ITT-E Population

[75] - ITT-E Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with any AE, AELD or AE with grade 1, 2, 3 or 4 toxicity over 48 weeks by Baseline third agent treatment class

End point title	Number of participants with any AE, AELD or AE with grade 1, 2, 3 or 4 toxicity over 48 weeks by Baseline third agent treatment class
-----------------	---

End point description:

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any AE, AELD or AE with maximum grade toxicity experienced by any one participant over 48 weeks by Baseline third agent class (INI, NNRTI, or PI) was summarized. AEs were graded using DAIDS grading table for grading severity of adult and pediatric adverse events. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 48 weeks

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[76]	256 ^[77]		
Units: Participants				
Any AE, NNRTI, n=131, 134	102	98		
Any AE, INI, n=46, 48	38	34		
Any AE, PI, n=75, 74	60	58		
NNRTI, Maximum toxicity Grade 1 AE, n=131, 134	69	72		
NNRTI, Maximum toxicity Grade 2 AE, n=131, 134	27	23		
NNRTI, Maximum toxicity Grade 3 AE, n=131, 134	5	2		
NNRTI, Maximum toxicity Grade 4 AE, n=131, 134	1	1		
INI, Maximum toxicity Grade 1 AE, n=46, 48	28	20		
INI, Maximum toxicity Grade 2 AE, n=46, 48	7	12		
INI, Maximum toxicity Grade 3 AE, n=46, 48	2	2		
INI, Maximum toxicity Grade 4 AE, n=46, 48	1	0		

PI, Maximum toxicity Grade 1 AE, n=75, 74	31	30		
PI, Maximum toxicity Grade 2 AE, n=75, 74	23	18		
PI, Maximum toxicity Grade 3 AE, n=75, 74	4	9		
PI, Maximum toxicity Grade 4 AE, n=75, 74	2	1		
AELD, NNRTI, n=131, 134	3	0		
AELD, INI, n=46, 48	2	0		
AELD, PI, n=75, 74	4	2		

Notes:

[76] - Safety Population

[77] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with maximum post-baseline emergent chemistry toxicities over 48 weeks by Baseline third agent treatment class

End point title	Number of participants with maximum post-baseline emergent chemistry toxicities over 48 weeks by Baseline third agent treatment class
-----------------	---

End point description:

Blood samples were collected to evaluate ALT, albumin, ALP, AST, total bilirubin, chloride, creatinine, glucose, potassium, phosphate, sodium, BUN, total carbon dioxide, lipase, creatine phosphokinase and creatinine clearance. Value at Day 1 was considered as Baseline. Number of participants who experienced maximum toxicity grade post-Baseline in chemistry parameters over 48 weeks by Baseline third agent treatment class (INI, NNRTI, PI) was summarized. Clinical chemistry toxicities were graded using DAIDS grading table for grading severity of adult and pediatric adverse events. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 48 weeks

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[78]	256 ^[79]		
Units: Participants				
NNRTI, Grade 1, n=131, 134	47	42		
NNRTI, Grade 2, n=131, 134	32	48		
NNRTI, Grade 3, n=131, 134	13	13		
NNRTI, Grade 4, n=131, 134	2	3		
INI, Grade 1, n= 46, 48	13	11		
INI, Grade 2, n= 46, 48	19	15		
INI, Grade 3, n= 46, 48	1	1		
INI, Grade 4, n= 46, 48	3	2		
PI, Grade 1, n= 75, 74	35	25		
PI, Grade 2, n= 75, 74	10	23		
PI, Grade 3, n= 75, 74	8	9		

PI, Grade 4, n= 75, 74	0	4		
------------------------	---	---	--	--

Notes:

[78] - Safety Population

[79] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with maximum post-Baseline emergent hematology toxicities over 48 weeks by Baseline third agent treatment class

End point title	Number of participants with maximum post-Baseline emergent hematology toxicities over 48 weeks by Baseline third agent treatment class
-----------------	--

End point description:

Blood samples were collected to evaluate hemoglobin, hematocrit, basophils, eosinophils, lymphocytes, monocytes, neutrophils, MCV, RBC count, WBC count and platelet count. Value at Day 1 was considered as Baseline. Number of participants who experienced maximum toxicity grade post-Baseline in hematology parameters over 48 weeks by Baseline third agent treatment class (INSTI, NNRTI, PI) was summarized. Hematology toxicities were graded using DAIDS grading table for grading severity of adult and pediatric adverse events. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 48 weeks

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[80]	256 ^[81]		
Units: Participants				
NNRTI; Grade 1; n= 131, 134	5	3		
NNRTI; Grade 2; n= 131, 134	1	1		
NNRTI; Grade 3; n= 131, 134	1	1		
NNRTI; Grade 4; n= 131, 134	0	1		
INI; Grade 1; n= 46, 48	2	2		
INI; Grade 2; n= 46, 48	1	0		
INI; Grade 3; n= 46, 48	0	0		
INI; Grade 4; n= 46, 48	0	0		
PI; Grade 1; n= 75, 74	4	6		
PI; Grade 2; n= 75, 74	1	1		
PI; Grade 3; n= 75, 74	2	0		
PI; Grade 4; n= 75, 74	0	0		

Notes:

[80] - Safety Population

[81] - Safety Population

Statistical analyses

Secondary: Number of participants with observed genotypic resistance for participants meeting virologic withdrawal criteria by Baseline third agent treatment class

End point title	Number of participants with observed genotypic resistance for participants meeting virologic withdrawal criteria by Baseline third agent treatment class
-----------------	--

End point description:

For all participants who meet virologic withdrawal criteria, plasma samples with HIV-1 RNA level ≥ 200 c/mL were to be analyzed in an attempt to obtain genotype data on as many samples as possible. Samples for drug resistance testing (genotypic) were to be collected at Day 1. Number of participants with genotypic resistance to CAR and to DTG or RPV for those meeting virologic withdrawal criteria in subgroups stratified based on Baseline third agent treatment class (INSTI, NNRTI, PI) were to be summarized. This outcome has not been analyzed as the number of participants was low (1 CVW per arm) and summaries by Baseline third agent were not provided. Therefore, data are not available for this outcome measure due to the insufficient number of participants with events.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[82]	0 ^[83]		
Units: Participants				

Notes:

[82] - CVW Resistance Population

[83] - CVW Resistance Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with observed phenotypic resistance for participants meeting virologic withdrawal criteria by Baseline third agent treatment class

End point title	Number of participants with observed phenotypic resistance for participants meeting virologic withdrawal criteria by Baseline third agent treatment class
-----------------	---

End point description:

For all participants who meet virologic withdrawal criteria, plasma samples with HIV-1 RNA level ≥ 200 c/mL were to be analyzed in an attempt to obtain phenotype data on as many samples as possible. Samples for drug resistance testing (phenotypic) were to be collected at Day 1. Number of participants with phenotypic resistance to CAR and to DTG or RPV for those meeting virologic withdrawal criteria in subgroups stratified based on Baseline third agent treatment class (INSTI, NNRTI, PI) were to be summarized. This outcome was not analyzed as the number of participants was low (1 CVW per arm) and summaries by Baseline third agent were not provided. Therefore, data are not available for this outcome measure due to the insufficient number of participants with events.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[84]	0 ^[85]		
Units: Participants				

Notes:

[84] - CVW Resistance Population

[85] - CVW Resistance Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in fasting lipids at Weeks 24 and 48 by Baseline third agent treatment class

End point title	Change from Baseline in fasting lipids at Weeks 24 and 48 by Baseline third agent treatment class
-----------------	---

End point description:

Blood samples were collected at Baseline (Day 1), Weeks 24 and 48 to assess fasting lipids which included total cholesterol (CHO), LDL cholesterol, HDL cholesterol and triglycerides. Change from Baseline was calculated as value at indicated time point minus Baseline value. 99999 indicates data was not available due to insufficient number of participants to analyze the data. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), Week 24 and Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[86]	256 ^[87]		
Units: mmol/ mL				
arithmetic mean (standard deviation)				
CHO, Week 24, overall, n=228, 223	3.239 (± 18.1556)	2.375 (± 14.8357)		
CHO, Week 48, overall, n=221, 218	3.596 (± 18.7072)	2.472 (± 14.7202)		
CHO, Week 24, NNRTI, n=0, 118	99999 (± 99999)	3.383 (± 13.3685)		
CHO, Week 48, NNRTI, n=0, 118	99999 (± 99999)	4.099 (± 13.8992)		
CHO, Week 24, INI, n=0, 44	99999 (± 99999)	1.288 (± 14.8933)		
CHO, Week 48, INI, n=0, 43	99999 (± 99999)	0.524 (± 15.3143)		
CHO, Week 24, PI, n=0, 61	99999 (± 99999)	1.211 (± 17.3972)		
CHO, Week 48, PI, n=0, 57	99999 (± 99999)	0.575 (± 15.7475)		

HDL CHO direct, Overall, Week 24, n=228, 223	0.017 (± 18.7575)	-2.478 (± 16.6754)		
HDL CHO direct, Overall, Week 48, n=221, 218	3.975 (± 21.1039)	3.095 (± 18.8909)		
HDL CHO direct, NNRTI, Week 24, n=0, 118	99999 (± 99999)	0.062 (± 15.9300)		
HDL CHO direct, NNRTI, Week 48, n=0, 118	99999 (± 99999)	4.818 (± 16.2253)		
HDL CHO direct, INI, Week 24, n=0, 44	99999 (± 99999)	-4.968 (± 16.2973)		
HDL CHO direct, INI, Week 48, n=0, 43	99999 (± 99999)	0.539 (± 22.6496)		
HDL CHO direct, PI, Week 24, n=0, 61	99999 (± 99999)	-5.594 (± 17.7923)		
HDL CHO direct, PI, Week 48, n=0, 57	99999 (± 99999)	1.457 (± 20.8346)		
LDL CHO calculation, Overall, Week 24, n=224, 217	11.504 (± 36.9087)	6.196 (± 24.0104)		
LDL CHO calculation, Overall, Week 48, n=215, 211	8.257 (± 33.0405)	3.258 (± 22.3644)		
LDL CHO calculation, NNRTI, Week 24, n=0, 116	99999 (± 99999)	6.816 (± 20.9081)		
LDL CHO calculation, NNRTI, Week 48, n=0, 114	99999 (± 99999)	4.920 (± 20.9300)		
LDL CHO calculation, INI, Week 24, n=0, 44	99999 (± 99999)	6.355 (± 24.1747)		
LDL CHO calculation, INI, Week 48, n=0, 43	99999 (± 99999)	3.490 (± 23.3198)		
LDL CHO calculation, PI, Week 24, n=0, 57	99999 (± 99999)	4.813 (± 29.5705)		
LDL CHO calculation, PI, Week 48, n=0, 54	99999 (± 99999)	-0.434 (± 24.4332)		
Triglycerides, Overall, Week 24, n=228, 223	0.096 (± 55.6357)	8.649 (± 48.8249)		
Triglycerides, Overall, Week 48, n=221, 218	3.605 (± 54.4914)	11.068 (± 54.6321)		
Triglycerides, NNRTI, Week 24, n=0, 118	99999 (± 99999)	6.867 (± 44.8605)		
Triglycerides, NNRTI, Week 48, n=0, 118	99999 (± 99999)	10.215 (± 58.4055)		
Triglycerides, INI, Week 24, n=0, 44	99999 (± 99999)	8.386 (± 54.1265)		
Triglycerides, INI, Week 48, n=0, 43	99999 (± 99999)	4.644 (± 48.8708)		
Triglycerides, PI, Week 24, n=0, 61	99999 (± 99999)	12.283 (± 52.6943)		
Triglycerides, PI, Week 48, n=0, 57	99999 (± 99999)	17.681 (± 50.6912)		

Notes:

[86] - Safety Population

[87] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in pre-specified treatment symptoms using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase

End point title	Change from Baseline in pre-specified treatment symptoms using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase
-----------------	---

End point description:

Symptom Distress Module, also called HIV Symptom Index or Symptoms Impact Questionnaire, is a 20-item self-reported measure that addresses presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Symptom count is based on which of the 20 symptoms were present in participant. Symptom count is sum of number of symptoms present and ranges from 0(none) to 20(all). Symptom bother score is based on score for each symptom present ranging from 1(it doesn't bother me) to 4(it bothers me a lot). Symptom bother score is unweighted sum of the bother item scores for each symptom and ranges from 0(minimum) to 80(maximum). Last observation carried forward (LOCF) was used as primary method of analysis. Change from Baseline was calculated as value at indicated time point minus Baseline value. Day 1 was considered as Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles)

End point type	Secondary
End point timeframe:	
Baseline (Day 1), Week 4, Week 24 and Week 48	

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[88]	256 ^[89]		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Symptom count, Week 4, n=212, 197	-1.6 (± 4.19)	0.2 (± 4.26)		
Symptom count, Week 24, n=214, 201	-0.8 (± 5.19)	-0.2 (± 4.06)		
Symptom count, Week 48, n=214, 201	-0.4 (± 5.52)	0.0 (± 4.49)		
Symptom Bother Score, Week 4, n=212, 197	-3.0 (± 7.25)	-0.8 (± 7.82)		
Symptom Bother Score, Week 24, n=214, 201	-1.7 (± 8.47)	-1.3 (± 8.53)		
Symptom Bother Score, Week 48, n=214, 201	-1.4 (± 8.32)	-0.7 (± 9.03)		

Notes:

[88] - ITT-E Population

[89] - ITT-E Population

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.94 ^[90]
Method	ANCOVA

Notes:

[90] - P-value for interaction between treatment group and Baseline symptom bother score (Week 4)

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Estimates are calculated from an ANCOVA model adjusting for age, Baseline third agent, gender, race and Baseline score.	
Comparison groups	DTG + RPV v Current antiretroviral regimen

Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[91]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-2.924
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.26
upper limit	-1.588

Notes:

[91] - P value to assess difference between treatment groups (Week 4)

Statistical analysis title	Statistical Analysis 3
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.001 ^[92]
Method	ANCOVA

Notes:

[92] - P-value for interaction between treatment group and Baseline symptom bother score (Week 24)

Statistical analysis title	Statistical Analysis 4
Statistical analysis description:	
Estimates are calculated from an ANCOVA model adjusting for age, Baseline third agent, gender, race and Baseline score.	
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.11 ^[93]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1.192
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.656
upper limit	0.271

Notes:

[93] - P value to assess difference between treatment groups (Week 24)

Statistical analysis title	Statistical Analysis 5
Comparison groups	DTG + RPV v Current antiretroviral regimen

Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.048 ^[94]
Method	ANCOVA

Notes:

[94] - P-value for interaction between treatment group and Baseline symptom bother score (Week 48)

Statistical analysis title	Statistical Analysis 6
-----------------------------------	------------------------

Statistical analysis description:

Estimates are calculated from an ANCOVA model adjusting for age, Baseline third agent, gender, race and Baseline score.

Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.038 ^[95]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-1.569
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.048
upper limit	-0.09

Notes:

[95] - P value to assess difference between treatment groups (Week 48)

Secondary: Change from Baseline in pre-specified treatment symptoms using the Symptom Distress Module at Weeks 56, 76, 100 and 148-DTG+RPV early switch group through Early and Late Switch Phase

End point title	Change from Baseline in pre-specified treatment symptoms using the Symptom Distress Module at Weeks 56, 76, 100 and 148-DTG+RPV early switch group through Early and Late Switch Phase ^[96]
-----------------	--

End point description:

Symptom Distress Module, also called the HIV Symptom Index or Symptoms Impact Questionnaire, is a 20-item self-reported measure that addresses presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Symptom count is based on which of the 20 symptoms were present in participant. Symptom count is the sum of number of symptoms present and ranges from 0 (none) to 20 (all). Symptom bother score is based on score for each symptom present ranging from 1 (it doesn't bother me) to 4 (it bothers me a lot). Symptom bother score is unweighted sum of the bother item scores for each symptom. Symptom bother score ranges from 0 (minimum bother score) to 80 (maximum bother score). LOCF was used as primary method of analysis. Change from Baseline was calculated as value at indicated time point minus Baseline value. Day 1 was considered as Baseline value. Only those participants with data available at the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), Week 56, Week 76, Week 100 and Week 148

Notes:

[96] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period.

End point values	DTG + RPV			
Subject group type	Reporting group			
Number of subjects analysed	214 ^[97]			
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Symptom count, Week 56	-0.9 (± 4.99)			
Symptom count, Week 76	-0.2 (± 5.42)			
Symptom count, Week 100	-0.4 (± 5.08)			
Symptom count, Week 148	-0.6 (± 5.24)			
Symptom Bother Score, Week 56	-1.6 (± 8.52)			
Symptom Bother Score, Week 76	-0.9 (± 8.84)			
Symptom Bother Score, Week 100	-0.8 (± 8.71)			
Symptom Bother Score, Week 148	-0.8 (± 9.15)			

Notes:

[97] - ITT-E Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from LS Baseline in pre-specified treatment symptoms using the Symptom Distress Module at Weeks 56, 76, 100 and 148 - CAR Late Switch group through Late Switch Phase

End point title	Change from LS Baseline in pre-specified treatment symptoms using the Symptom Distress Module at Weeks 56, 76, 100 and 148 - CAR Late Switch group through Late Switch Phase
-----------------	--

End point description:

Symptom Distress Module, also called HIV Symptom Index or Symptoms Impact Questionnaire is a 20-item self-reported measure that addresses presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Symptom count is based on which of the 20 symptoms were present in participant. Symptom count is sum of symptoms present and ranges from 0(none) to 20(all). Symptom bother score is based on score for each symptom present ranging from 1(it doesn't bother me) to 4(it bothers me a lot). Symptom bother score is unweighted sum of bother item scores for each symptom and ranges from 0(minimum) to 80(maximum). Last observation carried forward (LOCF) was used as primary method of analysis. Change from LS Baseline was calculated as value at indicated time point minus LS Baseline value. Value at Week 48 was considered as LS Baseline value. Only participants with data available at specified time points were analyzed (represented by n=X in the category titles)

End point type	Secondary
----------------	-----------

End point timeframe:

LS Baseline (Week 48), Week 56, Week 76, Week 100 and Week 148

End point values	Current antiretroviral regimen			
Subject group type	Reporting group			
Number of subjects analysed	238 ^[98]			
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Symptom count, Week 56, n=186	-0.7 (± 4.38)			
Symptom count, Week 76, n=188	0.1 (± 4.19)			
Symptom count, Week 100, n=188	0.0 (± 4.35)			

Symptom count, Week 148, n=188	0.4 (± 4.92)			
Symptom Bother Score, Week 56, n=186	-2.0 (± 8.11)			
Symptom Bother Score, Week 76, n=188	-0.4 (± 8.33)			
Symptom Bother Score, Week 100, n=188	-0.4 (± 9.17)			
Symptom Bother Score, Week 148, n=188	0.7 (± 9.57)			

Notes:

[98] - LS ITT-E Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline treatment satisfaction using the HIV treatment satisfaction questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase

End point title	Change from Baseline treatment satisfaction using the HIV treatment satisfaction questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase
-----------------	---

End point description:

HIV TSQ is a 10-item self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience, flexibility. Each item is scored 0 (very dissatisfied, inconvenient) to 6 (very satisfied, convenient). The items are summed up to produce a treatment satisfaction total score (0 to 60) and 2 subscale scores: general satisfaction/clinical and lifestyle/ease subscales (0 to 30). Higher scores indicated greater treatment satisfaction as compared to the past few weeks. The HIV TSQ was administered as a paper questionnaire. Total score, lifestyle/ease score and General satisfaction/CS have been summarized. LOCF was used as primary method of analysis. Value obtained at Day 1 was considered as Baseline value. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), Week 4, Week 24 and Week 48

End point values	DTG + RPV	Current antiretroviral regimen		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252 ^[99]	256 ^[100]		
Units: Scores on a scale				
median (full range (min-max))				
Total score, Week 4, n=250, 249	0.0 (-16 to 33)	0.0 (-25 to 21)		
Total score, Week 24, n=252, 254	1.0 (-18 to 33)	0.0 (-28 to 28)		
Total score, Week 48, n=252, 254	0.5 (-24 to 33)	0.0 (-28 to 20)		
lifestyle/ease Sub-score, Week 4, n=248, 249	0.0 (-7 to 15)	0.0 (-9 to 13)		
lifestyle/ease Sub-score, Week 24, n=252, 254	0.0 (-11 to 15)	0.0 (-14 to 12)		
lifestyle/ease Sub-score, Week 48, n=252, 254	0.0 (-13 to 16)	0.0 (-14 to 13)		
General Satisfaction/CS, Week 4, n=249, 249	0.0 (-10 to 18)	0.0 (-16 to 13)		

General Satisfaction/CS, Week 24, n=252, 254	0.0 (-7 to 18)	0.0 (-14 to 17)		
General Satisfaction/CS, Week 48, n=252, 254	0.0 (-14 to 18)	0.0 (-14 to 10)		

Notes:

[99] - ITT-E Population

[100] - ITT-E Population

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.002 ^[101]
Method	Wilcoxon rank sum test

Notes:

[101] - P-value to assess HIVTSQs Total Score difference between treatment groups (Week 4)

Statistical analysis title	Statistical Analysis 2
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[102]
Method	Wilcoxon rank sum test

Notes:

[102] - P-value to assess HIVTSQs Total Score difference between treatment groups (Week 24)

Statistical analysis title	Statistical Analysis 3
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.024 ^[103]
Method	Wilcoxon rank sum test

Notes:

[103] - P-value to assess HIVTSQs Total score difference between treatment groups (Week 48)

Statistical analysis title	Statistical Analysis 4
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[104]
Method	Wilcoxon rank sum test

Notes:

[104] - P-value to assess HIVTSQs lifestyle/ease sub- score difference between treatment groups (Week 4)

Statistical analysis title	Statistical Analysis 5
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[105]
Method	Wilcoxon rank sum test

Notes:

[105] - P-value to assess HIVTSQs lifestyle/ease sub- score difference between treatment groups (Week 24)

Statistical analysis title	Statistical Analysis 6
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.005 ^[106]
Method	Wilcoxon rank sum test

Notes:

[106] - P-value to assess HIVTSQs lifestyle/ease sub- score difference between treatment groups (Week 48)

Statistical analysis title	Statistical Analysis 7
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.063 ^[107]
Method	Wilcoxon rank sum test

Notes:

[107] - P-value to assess HIVTSQs General satisfaction/CS sub- score difference between treatment groups (Week 4)

Statistical analysis title	Statistical Analysis 8
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.002 ^[108]
Method	Wilcoxon rank sum test

Notes:

[108] - P-value to assess HIVTSQs General satisfaction/CS sub- score difference between treatment groups (Week 24)

Statistical analysis title	Statistical Analysis 9
Comparison groups	DTG + RPV v Current antiretroviral regimen
Number of subjects included in analysis	508
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.099 ^[109]
Method	Wilcoxon rank sum test

Notes:

[109] - P-value to assess HIVTSQs General satisfaction/CS sub- score difference between treatment groups (Week 48)

Secondary: Change from Baseline treatment satisfaction using HIV TSQ at Weeks 56, 76, 100 and 148 - DTG+RPV early switch group through Early and Late Switch Phase

End point title	Change from Baseline treatment satisfaction using HIV TSQ at Weeks 56, 76, 100 and 148 - DTG+RPV early switch group through Early and Late Switch Phase ^[110]
-----------------	--

End point description:

HIV TSQ is a 10-item self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience, flexibility. Each item is scored 0 (very dissatisfied, inconvenient) to 6 (very satisfied, convenient). The items are summed up to produce a treatment satisfaction total score (0 to 60) and 2 subscale scores: general satisfaction/clinical and lifestyle/ease subscales (0 to 30). Higher scores indicated greater treatment satisfaction as compared to the past few weeks. The HIV TSQ was administered as a paper questionnaire. Total score, lifestyle/ease score and General satisfaction/CS have been summarized. LOCF was used as primary method of analysis. Value obtained at Day 1 was considered as Baseline value. Change from Baseline was calculated as value at indicated time point minus Baseline value.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), Week 56, Week 76, Week 100 and Week 148

Notes:

[110] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period.

End point values	DTG + RPV			
Subject group type	Reporting group			
Number of subjects analysed	252 ^[111]			
Units: Scores on a scale				
median (full range (min-max))				
Total score, Week 56	0.0 (-42 to 33)			
Total score, Week 76	0.5 (-35 to 33)			
Total score, Week 100	0.0 (-17 to 33)			
Total score, Week 148	1.0 (-23 to 32)			
Lifestyle/ease Sub-score, Week 56	0.0 (-23 to 16)			
Lifestyle/ease Sub-score, Week 76	0.0 (-19 to 16)			
Lifestyle/ease Sub-score, Week 100	0.0 (-13 to 16)			
Lifestyle/ease Sub-score, Week 148	0.0 (-13 to 15)			
General Satisfaction/CS, Week 56	0.0 (-19 to 18)			
General Satisfaction/CS, Week 76	0.0 (-16 to 17)			
General Satisfaction/CS, Week 100	0.0 (-13 to 17)			
General Satisfaction/CS, Week 148	0.0 (-12 to 17)			

Notes:

[111] - ITT-E Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from LS Baseline treatment satisfaction using HIV TSQ at Weeks 56, 76, 100 and 148 - CAR Late Switch group through Late Switch Phase

End point title	Change from LS Baseline treatment satisfaction using HIV TSQ at Weeks 56, 76, 100 and 148 - CAR Late Switch group through Late Switch Phase
End point description: HIV TSQ is a 10-item self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience, flexibility. Each item is scored 0 (very dissatisfied, inconvenient) to 6 (very satisfied, convenient). The items are summed up to produce a treatment satisfaction total score (0 to 60) and 2 subscale scores: general satisfaction/clinical and lifestyle/ease subscales (0 to 30). Higher scores indicated greater treatment satisfaction as compared to the past few weeks. The HIV TSQ was administered as a paper questionnaire. Total score, lifestyle/ease score and General satisfaction/CS have been summarized. LOCF was used as primary method of analysis. Value obtained at Week 48 was considered as LS Baseline value. Change from LS Baseline was calculated as value at indicated time point minus LS Baseline value. Only those participants with data available at the specified time points were analyzed.	
End point type	Secondary
End point timeframe: LS Baseline (Week 48), Week 56, Week 76, Week 100 and Week 148	

End point values	Current antiretroviral regimen			
Subject group type	Reporting group			
Number of subjects analysed	236 ^[112]			
Units: Scores on a scale				
median (full range (min-max))				
Total score, Week 56	0.0 (-31 to 31)			
Total score, Week 76	0.0 (-37 to 31)			
Total score, Week 100	0.0 (-37 to 26)			
Total score, Week 148	0.0 (-37 to 26)			
Lifestyle/ease Sub-score, Week 56	0.0 (-14 to 16)			
Lifestyle/ease Sub-score, Week 76	0.0 (-21 to 16)			
Lifestyle/ease Sub-score, Week 100	0.0 (-21 to 18)			
Lifestyle/ease Sub-score, Week 148	0.0 (-21 to 16)			
General Satisfaction/CS, Week 56	0.0 (-17 to 16)			
General Satisfaction/CS, Week 76	0.0 (-17 to 16)			
General Satisfaction/CS, Week 100	0.0 (-17 to 14)			
General Satisfaction/CS, Week 148	0.0 (-17 to 13)			

Notes:

[112] - LS ITT-E Population

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Percentage of participants with plasma HIV-1 RNA <50 c/mL at Weeks 100 and 148 using the Snapshot algorithm-DTG+RPV early switch group through Early and Late Switch Phase

End point title	Percentage of participants with plasma HIV-1 RNA <50 c/mL at Weeks 100 and 148 using the Snapshot algorithm-DTG+RPV early switch group through Early and Late Switch Phase ^[113]
-----------------	---

End point description:

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Percentage of participants with plasma HIV 1 RNA < 50 c/mL using the FDA snapshot algorithm was assessed. Virologic success or

failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the window of the visit of interest.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Weeks 100 and 148

Notes:

[113] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period.

End point values	DTG + RPV			
Subject group type	Reporting group			
Number of subjects analysed	252 ^[114]			
Units: Percentage of participants				
number (not applicable)				
Week 100	88			
Week 148	85			

Notes:

[114] - ITT-E Population

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Change from Baseline in CD4+ lymphocyte count at Weeks 100 and 148-DTG+RPV early switch group through Early and Late Switch Phase

End point title	Change from Baseline in CD4+ lymphocyte count at Weeks 100 and 148-DTG+RPV early switch group through Early and Late Switch Phase ^[115]
-----------------	--

End point description:

Blood samples were collected for CD4+ cell count assessment by flow cytometry. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline (Day 1), Weeks 100 and 148

Notes:

[115] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period.

End point values	DTG + RPV			
Subject group type	Reporting group			
Number of subjects analysed	252 ^[116]			
Units: Cells/mm ³				
arithmetic mean (standard deviation)				
Week 100; n=224	25.1 (± 156.31)			
Week 148; n=212	39.9 (± 174.40)			

Notes:

[116] - ITT-E Population

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Percentage of participants with plasma HIV-1 RNA <50 c/mL at Weeks 100 and 148 using the Snapshot algorithm-CAR Late Switch group through Late Switch Phase

End point title	Percentage of participants with plasma HIV-1 RNA <50 c/mL at Weeks 100 and 148 using the Snapshot algorithm-CAR Late Switch group through Late Switch Phase
-----------------	---

End point description:

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Percentage of participants with plasma HIV 1 RNA < 50 c/mL using the FDA snapshot algorithm was assessed. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the window of the visit of interest.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Weeks 100 and 148

End point values	Current antiretroviral regimen			
Subject group type	Reporting group			
Number of subjects analysed	238 ^[117]			
Units: Percentage of participants				
number (not applicable)				
Week 100	90			
Week 148	87			

Notes:

[117] - LS ITT-E Population

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Change from LS Baseline in CD4+ lymphocyte count at Weeks 100 and 148-CAR Late Switch group through Late Switch Phase

End point title	Change from LS Baseline in CD4+ lymphocyte count at Weeks 100 and 148-CAR Late Switch group through Late Switch Phase
-----------------	---

End point description:

Blood samples were collected for CD4+ cell count assessment by flow cytometry. Change from LS Baseline was calculated as value at indicated time point minus LS Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

LS Baseline (Week 48), Weeks 100 and 148

End point values	Current antiretroviral regimen			
Subject group type	Reporting group			
Number of subjects analysed	238 ^[118]			
Units: Cells/mm ³				
arithmetic mean (standard deviation)				
Week 100; n=217	-3.3 (± 180.82)			
Week 148; n=207	3.7 (± 205.29)			

Notes:

[118] - LS ITT-E Population

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Data presented for DTG+RPV (Early Switch) and CAR (Early Switch) represent safety events up to Week 52. Data for DTG+RPV (Early+Late Switch) represents safety events up to Week 148 and CAR (Late Switch) represents safety events from Week 52 to Week 148.

Adverse event reporting additional description:

On treatment SAEs and non-serious AEs were reported for the Safety Population for DTG+RPV (Early Switch), CAR (Early Switch) and DTG+RPV (Early+Late Switch). LS Safety Population was used for CAR (Late Switch arm).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.0
--------------------	------

Reporting groups

Reporting group title	DTG + RPV (Early Switch)
-----------------------	--------------------------

Reporting group description:

Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase.

Reporting group title	CAR (Early Switch)
-----------------------	--------------------

Reporting group description:

Participants continued to receive their current antiretroviral regimen (two nucleoside reverse transcriptase inhibitors [NRTIs] + a third agent). A third agent included either an: integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). CAR was administered according to the approved labeling in an open-label fashion up to Week 52 during early switch phase.

Reporting group title	DTG + RPV (Early + Late Switch)
-----------------------	---------------------------------

Reporting group description:

Participants received DTG 50 mg + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.

Reporting group title	CAR (Late Switch)
-----------------------	-------------------

Reporting group description:

At Week 52, participants who received CAR during the early switch phase, with HIV-1 RNA <50 c/mL, switched to DTG 50 mg + RPV 25 mg once daily and were followed until Week 148.

Serious adverse events	DTG + RPV (Early Switch)	CAR (Early Switch)	DTG + RPV (Early + Late Switch)
Total subjects affected by serious adverse events			
subjects affected / exposed	10 / 252 (3.97%)	13 / 256 (5.08%)	34 / 252 (13.49%)
number of deaths (all causes)	0	1	1
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	0 / 252 (0.00%)	1 / 256 (0.39%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hodgkin's disease mixed cellularity stage unspecified			
subjects affected / exposed	1 / 252 (0.40%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	0 / 252 (0.00%)	1 / 256 (0.39%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Plasmablastic lymphoma			
subjects affected / exposed	1 / 252 (0.40%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma of colon			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anogenital warts			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuroendocrine carcinoma			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-small cell lung cancer			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal squamous cell carcinoma			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural neoplasm			

subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular germ cell tumour mixed			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid cancer			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Peripheral artery stenosis			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 252 (0.00%)	1 / 256 (0.39%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Reproductive system and breast disorders			
Ovarian cyst			

subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pneumothorax			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 252 (0.00%)	1 / 256 (0.39%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Panic attack			
subjects affected / exposed	1 / 252 (0.40%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	1 / 252 (0.40%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Wrist fracture			
subjects affected / exposed	1 / 252 (0.40%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibula fracture			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural pneumothorax			

subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wolff-Parkinson-White syndrome			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Toxic encephalopathy			
subjects affected / exposed	0 / 252 (0.00%)	1 / 256 (0.39%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery stenosis			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			

subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 252 (0.40%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Anal fistula			
subjects affected / exposed	0 / 252 (0.00%)	1 / 256 (0.39%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	1 / 252 (0.40%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis			
subjects affected / exposed	0 / 252 (0.00%)	1 / 256 (0.39%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer haemorrhage			

subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Drug-induced liver injury			
subjects affected / exposed	1 / 252 (0.40%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			

Thyroid mass			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Intervertebral disc protrusion			
subjects affected / exposed	0 / 252 (0.00%)	1 / 256 (0.39%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 252 (0.00%)	1 / 256 (0.39%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 252 (0.40%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis C			
subjects affected / exposed	0 / 252 (0.00%)	1 / 256 (0.39%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 252 (0.00%)	1 / 256 (0.39%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillar abscess			
subjects affected / exposed	0 / 252 (0.00%)	1 / 256 (0.39%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 252 (0.40%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Rectal abscess			
subjects affected / exposed	0 / 252 (0.00%)	1 / 256 (0.39%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroglossal cyst infection			
subjects affected / exposed	0 / 252 (0.00%)	1 / 256 (0.39%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis A			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	3 / 252 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute hepatitis B			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis bacterial			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			

subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shigella infection			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal osteomyelitis			
subjects affected / exposed	0 / 252 (0.00%)	0 / 256 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	CAR (Late Switch)		
Total subjects affected by serious adverse events			
subjects affected / exposed	22 / 238 (9.24%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hodgkin's disease mixed cellularity stage unspecified			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung neoplasm malignant			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Plasmablastic lymphoma			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Adenocarcinoma of colon				
subjects affected / exposed	0 / 238 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anogenital warts				
subjects affected / exposed	1 / 238 (0.42%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Neuroendocrine carcinoma				
subjects affected / exposed	0 / 238 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Non-small cell lung cancer				
subjects affected / exposed	0 / 238 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oropharyngeal squamous cell carcinoma				
subjects affected / exposed	1 / 238 (0.42%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pleural neoplasm				
subjects affected / exposed	0 / 238 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Testicular germ cell tumour mixed				
subjects affected / exposed	0 / 238 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thyroid cancer				
subjects affected / exposed	1 / 238 (0.42%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Vascular disorders				

Peripheral artery stenosis			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Death			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Ovarian cyst			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pneumothorax			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			

Panic attack			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Suicide attempt			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Wrist fracture			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fibula fracture			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Procedural pneumothorax			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Road traffic accident			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pericarditis			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Wolff-Parkinson-White syndrome			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Toxic encephalopathy			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Carotid artery stenosis			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Loss of consciousness			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Paraesthesia			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Transient ischaemic attack			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Gastrointestinal disorders			
Anal fistula			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis acute			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Proctitis			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Duodenal ulcer haemorrhage			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastric ulcer haemorrhage			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Melaena			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Oesophagitis			

subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Drug-induced liver injury			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystitis acute			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Thyroid mass			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Intervertebral disc protrusion			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			

subjects affected / exposed	0 / 238 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatitis C				
subjects affected / exposed	0 / 238 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	0 / 238 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Peritonsillar abscess				
subjects affected / exposed	0 / 238 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	0 / 238 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectal abscess				
subjects affected / exposed	0 / 238 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thyroglossal cyst infection				
subjects affected / exposed	0 / 238 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatitis A				
subjects affected / exposed	3 / 238 (1.26%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Acute hepatitis B				

subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Appendicitis			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthritis bacterial			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Diverticulitis			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis viral			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Shigella infection			
subjects affected / exposed	1 / 238 (0.42%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Staphylococcal osteomyelitis			
subjects affected / exposed	0 / 238 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	DTG + RPV (Early Switch)	CAR (Early Switch)	DTG + RPV (Early + Late Switch)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	107 / 252 (42.46%)	102 / 256 (39.84%)	167 / 252 (66.27%)
Nervous system disorders			
Headache			
subjects affected / exposed	24 / 252 (9.52%)	17 / 256 (6.64%)	37 / 252 (14.68%)
occurrences (all)	25	19	43
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	9 / 252 (3.57%)	3 / 256 (1.17%)	13 / 252 (5.16%)
occurrences (all)	9	3	14
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	22 / 252 (8.73%)	17 / 256 (6.64%)	35 / 252 (13.89%)
occurrences (all)	24	18	38
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	3 / 252 (1.19%)	9 / 256 (3.52%)	10 / 252 (3.97%)
occurrences (all)	3	9	10
Psychiatric disorders			
Insomnia			
subjects affected / exposed	9 / 252 (3.57%)	6 / 256 (2.34%)	18 / 252 (7.14%)
occurrences (all)	10	6	20
Depression			
subjects affected / exposed	10 / 252 (3.97%)	2 / 256 (0.78%)	17 / 252 (6.75%)
occurrences (all)	10	2	18
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	8 / 252 (3.17%)	19 / 256 (7.42%)	25 / 252 (9.92%)
occurrences (all)	9	20	28
Pain in extremity			
subjects affected / exposed	9 / 252 (3.57%)	5 / 256 (1.95%)	18 / 252 (7.14%)
occurrences (all)	9	6	19
Arthralgia			

subjects affected / exposed occurrences (all)	8 / 252 (3.17%) 10	4 / 256 (1.56%) 5	14 / 252 (5.56%) 17
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	27 / 252 (10.71%)	31 / 256 (12.11%)	52 / 252 (20.63%)
occurrences (all)	33	35	84
Syphilis			
subjects affected / exposed	8 / 252 (3.17%)	7 / 256 (2.73%)	27 / 252 (10.71%)
occurrences (all)	10	7	39
Upper respiratory tract infection			
subjects affected / exposed	7 / 252 (2.78%)	10 / 256 (3.91%)	26 / 252 (10.32%)
occurrences (all)	9	11	32
Influenza			
subjects affected / exposed	4 / 252 (1.59%)	12 / 256 (4.69%)	12 / 252 (4.76%)
occurrences (all)	4	13	12
Bronchitis			
subjects affected / exposed	7 / 252 (2.78%)	4 / 256 (1.56%)	16 / 252 (6.35%)
occurrences (all)	7	5	19
Urinary tract infection			
subjects affected / exposed	9 / 252 (3.57%)	2 / 256 (0.78%)	13 / 252 (5.16%)
occurrences (all)	9	2	13

Non-serious adverse events	CAR (Late Switch)		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	134 / 238 (56.30%)		
Nervous system disorders			
Headache			
subjects affected / exposed	23 / 238 (9.66%)		
occurrences (all)	29		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	6 / 238 (2.52%)		
occurrences (all)	6		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	19 / 238 (7.98%)		
occurrences (all)	20		

Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	13 / 238 (5.46%) 13		
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all) Depression subjects affected / exposed occurrences (all)	18 / 238 (7.56%) 20 5 / 238 (2.10%) 6		
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all) Pain in extremity subjects affected / exposed occurrences (all) Arthralgia subjects affected / exposed occurrences (all)	18 / 238 (7.56%) 19 12 / 238 (5.04%) 16 17 / 238 (7.14%) 19		
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all) Syphilis subjects affected / exposed occurrences (all) Upper respiratory tract infection subjects affected / exposed occurrences (all) Influenza subjects affected / exposed occurrences (all) Bronchitis	39 / 238 (16.39%) 55 20 / 238 (8.40%) 24 17 / 238 (7.14%) 25 13 / 238 (5.46%) 16		

subjects affected / exposed	11 / 238 (4.62%)		
occurrences (all)	14		
Urinary tract infection			
subjects affected / exposed	3 / 238 (1.26%)		
occurrences (all)	3		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 February 2015	Protocol was amended to include additional pharmacokinetic visits for the first 20 participants in the non-nucleoside reverse transcriptase inhibitor (NNRTI) subset who switch from Efavirenz (EFV) or Nevirapine (NVP) in the early switch phase and additional pharmacokinetic visits for all participants in the late switch phase, addition of stratification by planned participation in the dual-energy x-ray absorptiometry (DEXA) substudy, revisions to inclusion and exclusion criteria, revision to the definition of study completion, edits to the time and events table, revisions to suicidal risk monitoring section, and minor clarifications and corrections of typographical errors.
08 June 2015	Protocol was amended to include reasons for switch for Protease inhibitor (PI)-class aligned with other Antiretroviral therapy (ART) class switches, revisions to stratified analysis of the primary endpoint, revisions to virologic withdrawal criteria, references to study drug versus investigational product, and minor clarifications and corrections of typographical errors.
27 February 2018	Protocol was amended to include the introduction of commercially derived supplies of Dolutegravir (DTG) as IP; included statements to clarify that in Taiwan and Russia, the Symptoms Distress Module is not utilized as no validated translations are available. Two editorial revisions were made to aid clarity and correct a typographical error.
03 July 2018	<p>Changes were made to the protocol to manage and mitigate risks following identification of a potential safety issue related to neural tube defect in infants born to women with exposure to dolutegravir at the time of conception. The description of the dolutegravir and rilpivirine Investigator's brochures were updated to the current version.</p> <ul style="list-style-type: none">- The Risk Assessment table was updated to include language regarding risk and mitigation of neural tube defects.- Inclusion criterion number 5 was updated to exclude the double barrier method of contraception, which does not meet updated GlaxoSmithKline (GSK)/ViiV criteria for a highly effective method. Acceptable methods of contraception were clarified.- The Withdrawal Criteria were updated to include a reminder that females of reproductive potential who change their minds and desire to be pregnant or who do not wish to comply with the approved pregnancy avoidance methods, should also be withdrawn from the study.- The Time and Events Table. was updated to include a reminder for investigators to check at every visit that females of reproductive potential are avoiding pregnancy.- The References was revised to update the references for the dolutegravir Investigator's Brochure and the rilpivirine Investigator's Brochure to the current versions, and to include a new reference citing methods of highly effective contraception.
10 September 2019	Changes were made to the protocol applicable only in the Russian Federation. This country-specific amendment was to facilitate treatment of participants recruited in the Russian Federation with the DTG/RPV fixed dose combination (FDC) tablet to satisfy a regulatory requirement for data of participants recruited locally who have received the DTG/RPV FDC. The reference section was updated to include the current versions of the dolutegravir Investigator's Brochure and the rilpivirine Investigator's Brochure.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported